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Summary V
Summary
Dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) is
encoded on human chromosome 21 and triplication of this specific region leads to a
1.5-fold increased expression of DYRK1A in Down syndrome. Today there is a growing
interest in developing chemical probes for the functional characterization of kinases,
but to date just a small fraction of the human kinome can be effectively targeted
with selective small-molecule inhibitors to date. Harmine is one of the most potent
and selective inhibitors of DYRK1A presently available. Nevertheless, its inhibitory
effect on monoaminoxidase A (MAO A) limits the use of harmine as chemical probe
in animal experiments and as a therapeutic agent.
Therefore, the first part of this study aimed at the development of a harmine analogue
to get an improved inhibitor of DYRK1A without MAO A inhibitory activity. Based
on the known crystal structure of DYRK1A and on a model of the DYRK1A/harmine
complex, diversely substituted harmine analogues have been synthesized and tested for
their inhibitory potency for DYRK1A in in vitro assays. These experiments identified
AnnH75 as one of the most potent newly synthesized inhibitors of DYRK1A with an
IC50 value of 184 nM in radioactive assays, but without any inhibitory effect on MAO
A. Kinome profiling against a panel of 300 kinases at a concentration of 1 µM revealed
that AnnH75 inhibits only 4 off-target kinases by more than 90% (DYRK1B, CLK1,
CLK4, Haspin) leading to a Gini value of 0.625. Cell based assays showed a high cell
permeability and low cytotoxicity in HeLa and PC12 cells up to concentrations of 10
µM confirming AnnH75 as a usable, potent and specific inhibitor for investigations of
DYRK1A function in biological systems, cell assays and animal testing.
The dual specificity kinase activity is a defining feature of the DYRK family and
is essentially linked to the characteristic autoactivation mechanism of DYRKs. The
current model of the mechanism of tyrosine autophosphorylation in the DYRK family
is based on a study of the Drosophila DYRKs dDYRK2 and MNB, but has not been
verified for mammalian DYRK1A yet.
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Therefore, the second part of this study addressed to examine the mechanism of
dual specificity kinase activity in mammalian DYRK1A. Additionally, this study
investigated whether tyrosine phosphorylation is a strictly co-translational event or
whether it can still take place in mature DYRKs and to study the potential of
inhibitors to differentially target the tyrosine kinase form and the mature serine/
threonine-specific conformation of DYRK1A.
In vitro translation experiments showed that wild type DYRK1A as well as the Y321F
point mutant of DYRK1A retain the capacity of autophosphorylating tyrosine residues
after termination of in vitro translation. Accordingly, tyrosine kinase activity of
DYRK1A is not limited to a transient folding state that only exists during translation.
Furthermore, it can be concluded that the ability of DYRK1A for posttranslational
tyrosine autophosphorylation does not depend on the phosphorylation status of the
conserved tyrosine 321 in the activation loop. Finally, the postulated differences of
kinase inhibitor sensitivities for tyrosine autophosphorylation of mature DYRK1A
and the translational intermediate form of DYRK1A was not confirmed in this study
suggesting that the reported differences for DYRK2 are not conserved throughout the
DYRK family.
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Deutsche Zusammenfassung
Dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) ist auf
dem humanen Chromosom 21 kodiert und eine Verdreifachung dieser speziellen Region
führt zu einer 1,5 fach erhöhten Expression dieser Kinase bei Menschen mit Down
Syndrom. Das Interesse Substanzen zur funktionalen Charakterisierung von Kinasen
zu entwickeln wächst stetig, jedoch kann heutzutage immer noch nur ein kleiner Teil
des humanen Kinoms effektiv mit niedermolekularen Inhibitoren gehemmt werden.
Einer der potentesten, selektivsten und verfügbaren DYRK1A-Inhibitoren ist Harmin,
jedoch wird sein Einsatz in Tierexperimenten oder therapeutischen Studien durch die
ebenfalls starke Hemmung der Monoaminoxidase A (MAO A) limitiert.
Daher zielte der erste Teil dieser Arbeit auf die Entwicklung eines verbesserten
Harmin Analogons ohne inhibitorische Aktivität auf die MAO A ab. Basierend
auf bereits bekannten Kristallstrukturen von DYRK1A und Bindungsmodellen mit
Harmin wurden verschiedenst subtitutierte Harmin-Derivate synthetisiert und in in
vitro Assays auf ihre inhibitorische Potenz bezüglich DYRK1A getestet. AnnH75
wurde als einer der potentesten neu synthetisierten DYRK1A-Inhibitoren identifiziert.
Dieses Harmin Analogon hemmte DYRK1A mit einem IC50 Wert von 184 nM in
radioaktiven Assays und zeigte keine inhibitorische Aktivität auf die MAO A. Ein
Screening an 300 Kinasen zeigte, dass AnnH75 bei einer Konzentration von 1 µM
lediglich 4 off-target Kinasen (DYRK1B, CLK1, CLK4, Haspin) zu mehr als 90%
hemmt, was einem Gini Koeffizienten von 0,625 entspricht. Zellbasierte Assays zeigten
außerdem, dass AnnH75 eine hohe Zellpermeabilität besitzt, jedoch Konzentrationen
von bis zu 10 µM nur geringfügig cytotoxisch auf HeLa-Zellen und PC12-Zellen
wirken. Diese Ergebnisse bestätigen, dass AnnH75 als potenter und spezifischer
Inhibitor zur Erforschung von DYRK1A in biologischen Systemen, Zell-Assays und
Tierexperimenten eingesetzt werden kann.
Die duale Spezifität ist ein charakteristisches Merkmal der DYRK-Familie und trägt
essentiell zum spezifischen Autoaktivitätsmechanismus von DYRK-Kinasen bei. Das
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vorherrschende Modell zum Tyrosin Autophosphorylierungsmechanismus innerhalb
der DYRK-Familie basiert auf einer Studie mit den Drosophila DYRKs dDYRK2 und
MNB. Dieser Mechanismus wurde jedoch noch nicht für Säuger-DYRK1A bestätigt.
Der zweite Teil dieser Arbeit beschäftigte sich deshalb mit der Untersuchung des
Mechanismus der dualen Spezifität in Säuger-DYRK1A. Zusätzlich wurde erforscht,
ob die Tyrosin-Phosphorylierung strikt co-translational erfolgt oder ob dieses
Ereignis auch in der reifen Form der DYRK-Kinase stattfinden kann. Außerdem
diente die Studie der Überprüfung, ob Inhibitoren unterschiedliche Potenzen
bezüglich der Hemmung der Tyrosin-aktiven Kinasekonformation und der reifen
Serin/ Threonin-aktiven Konformation von DYRK1A aufweisen.
In vitro Translationsexperimente zeigten, dass sowohl der Wildtyp als auch die Y321F
Punktmutante von DYRK1A die Fähigkeit zur Tyrosin-Autophosphorylierung
auch nach Beendigung der in vitro Translation beibehalten. Dementsprechend
ist die Tyrosin-Kinaseaktivität von DYRK1A nicht auf einen transienten
Konformationsstatus während der Translation beschränkt. Vielmehr kann
man schlussfolgern, dass die Fähigkeit von DYRK1A zur posttranslationalen
Tyrosin-Autophosphorylierung unabhängig vom Phosphorylierungssatus des
konservierten Tyrosins 321 in der Aktivierungsschleife besteht. Schließlich
konnte der postulierte Sensitivitätsunterschied von Kinaseinhibitoren bezüglich
der Tyrosin-aktiven Kinasekonformation und der reifen Serin/ Threonin-aktiven
Konformation von DYRK1A nicht bestätigt werden. Vermutlich sind die für
DYRK2 dokumentierten Sensitivitätsunterschiede nicht innerhalb der DYRK-Familie
konserviert.
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1 Introduction
1.1 The human kinome
The human kinome comprises more than 500 protein kinases and represents about
2% of all human genes (Manning et al., 2002). There is one superfamily of 478 kinases
whose catalytic domains are related in sequence. This superfamily can be subdivided
into several groups with 143 families and 212 sub-families of increasing sequence
similarity and biochemical function (fig. 1). 50 of these kinase families are conserved
between yeast, invertebrate and mammalian kinomes, which shows the diversity
of essential functions mediated by kinases (Johnson, 2009). Further chromosomal
mapping revealed that 244 kinases map to disease loci or cancer amplicons (Manning
et al., 2002), and resulted in a growing interest in protein kinases as drug targets.
All protein kinases have a joint general structure of the kinase domain existing
of two lobes, the N- and the C-terminal lobe (Johnson et al., 1998). The smaller
N-terminal lobe consists of beta-sheets and connecting loops, which shape one
functionally important helix. This so called Helix-C is necessary for the catalysis
of ATP-transfer. The bigger C-terminal lobe consists mainly of α-helices and is
extremely stable (Endicott et al., 2012).
Besides of these two lobes, every protein kinase owns a specific sequence called
activation loop, which connects both N- and C-terminal lobes. Every activation loop
starts with the conserved tripeptide motif aspartate, phenylalanine, glycine (DFG)
and ends with the motif alanine, proline, glutamate (APE). This particular region
provides the docking site for the kinase substrates and phosphorylation on a specific
amino acid residue determines enzymatic activity in a great number of protein
kinases (Johnson et al., 1996).
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Figure 1: Kinome dendrogram.
The kinome dendrogram shows the sequence similarity between protein kinase domains, derived from
public sequences and gene prediction methods. DYRK family members are highlighted with a red circle
(description see below). Subdivision of superfamily in following groups: AGC: protein kinases A, G and C;
CAMK: Calcium/Calmodulin kinases; CK1: Casein kinase 1; CMGC: contains CDK, MAPK, GSK3, CLK;
STE: homologs of the yeast sterile kinases; GYC: guanylate cyclase: TK: tyrosine kinases; TKL: tyrosine
kinase - like. The kinome dendrogram is courtesy of Cell Signaling Technology.
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Both lobes are additionally joined by a loop called the hinge-region, which enables the
binding with ATP by forming an essential part of the ATP-binding pocket (Nolen,
Taylor and Ghosh, 2004). This bond is mediated through a very flexible, glycine rich
loop, which is also called the phosphate binding loop (P-loop) or Walker loop - named
after John Ernest Walker, who first reported about this motif (Walker et al., 1982).
The adenosine moiety of ATP binds to the hinge-region and the so-called P-loop
ensures the binding of metal ions, which protein kinases need as cofactors. In the
majority of kinases a ‘gatekeeper‘ residue precedes the hinge region; a specific amino
acid (typically methionine, threonine, leucine, phenylalanine or valine) controlling
the accessibility to the ATP-binding pocket (Zuccotto et al., 2010) (fig. 2).
Figure 2: General structure of kinase domains.
The inset selectively displays the critical components of the general structure of kinase domains: two lobes
(N-lobe and C-lobe), the activation loop with conserved motifs aspartate, phenylalanine, glycine (DFG)
and alanine, proline, glutamate (APE), helix-C, gatekeeper amino acid, hinge-region, P-loop, ATP, ion and
the autophosphorylation site within the activation loop,which many protein kinases need for activation.
The schematic overview is modified from Jura et al., 2011.
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1.1.1 The DYRK family and related protein kinases
One of the fundamental mechanisms in cells controlling nearly every aspect of cell
life is to phosphorylate proteins and as a consequence to regulate the activity of
these proteins. In this event, the γ-phosphate group from adenosine triphosphate
(ATP) is transferred to either aliphatic (serine or threonine) or aromatic (tyrosine)
hydroxyl groups of protein amino acid side chains (Cohen, 2002). In many cases, this
leads to conformational changes evoked by the polar charge of the phosphate group.
Protein kinases are enzymes specialized for this process and occur membrane-bound,
transmembranal, nuclear or cytoplasmatic according to the particular requirement
(Hanks and Hunter, 1995). They can be distinguished by their chemical activity and
the amino acid they phosphorylate. Most kinases act on serine or threonine and
only about 17 % of all kinases phosphorylate tyrosine residues. This prevalence is
also reflected by the distribution of the respective phosphorylation in humans. Thus
phosphorylated serine residues occur in approximately 86.4 %, phospho-threonine in
11.8 % and phospho-tyrosine only in 1.8 % of phosphoproteins (Olsen et al., 2006).
Only a few protein kinases are able to transfer the γ-phosphate group from ATP to
both aliphatic and aromatic hydroxyl groups of amino acid side chains (Lindberg
et al., 1992). One known kinase family with this so-called dual specificity is the
Dual Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase family, abbreviated
as DYRK. They belong to the protein kinase group CMGC, which comprises the
cyclin-dependent kinases (CDKs), mitogen-activated kinases (MAPKs), glycogen
synthase kinases 3 (GSK3), CDK-like kinases (CLKs), SR-rich protein kinase (SRPKs)
and homeodomain-interacting protein kinases (HIPKs) (Manning et al., 2002).
The human DYRK family consists of five isoforms divided into two classes, which are
referred to as DYRK1A and DYRK1B in class I, and DYRK2, DYRK3 and DYRK4
in class II (reviewed in Aranda et al., 2011). DYRKs have been described in mammals
first in 1996 (Kentrup et al., 1996) and are characterized by autophosphorylation
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on tyrosine residues, while substrates are phosphorylated on serine and threonine
residues (Himpel et al., 2001). Besides of their dual specificity, all family members
share a conserved kinase domain and a DYRK-homology-box (Becker and Joost,
1999), additionally class II DYRKs possess the N-terminal autophophorylation
accessory (NAPA) region (Kinstrie et al., 2010). However, the expression patterns,
subcellular localizations and functions differ within this kinase family. While
DYRK1A is ubiquitously expressed in adult and fetal tissues, for example DYRK4 is
expressed predominantly in adult rat testicles. Intracellular DYRK1A and DYRK1B
can be found generally in the nucleus, whereas the other DYRK members are
localized mainly in the cytoplasm (Becker et al., 1998, Leder et al., 1999, Alvarez et
al., 2003). And while DYRK2 is involved in the response to DNA damage through
p53 phosphorylation (Taira et al. 2007), DYRK1B plays critical roles in muscle
differentiation by regulatory effects on cell cycle progression, transcription, and cell
survival (Mercer and Friedman, 2006).
The autophosphorylation on a specific tyrosine residue within the activation loop in
order to attain full catalytic activity is not only characteristic for all DYRKs but
also some related kinases, such as HIPK2. This kinase is known to play an important
role as tumor suppressor and it has been shown that the tyrosine residue on position
354 in the activation-loop is a critical autophosphorylation site to acquire kinase
activation, substrate specificity, and subcellular localization (Siepi et al., 2013).
Mass spectroscopy revealed two cis-autophosphorylated sites in the activation-loop
suggesting a mechanism for HIPK2 activation through cis autophosphorylation (Siepi
et al., 2013, Saul et al., 2013). Some other protein kinases of the CMGC group are
also known to autophosphorylate on tyrosine residues in the activation loop, e.g.
GSK3 and CDKL5 (reviewed by Becker and Sippl., 2010). The related kinases CLKs
miss a conserved tyrosine in the activation loop, although these kinases are able to
autophosphorylate on tyrosine residues (Lee et al., 1996). Whether other CMGC
kinases can also target tyrosine residues, other than that in the activation loop,
remains an unanswered question.
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1.1.2 The protein kinase DYRK1A
DYRK1A was described as first mammalian DYRK family member in 1996 and is
encoded in the so-called Down syndrome critical region (DSCR) of chromosome 21 in
humans (Kentrup et al., 1996, Guimera et al., 1996). Triplication of this specific region
leads to the characteristic phenotype of Down syndrome (Korenberg et al., 1990) and
to a 1.5-fold increased expression of DYRK1A. This overexpression is suggested to
contribute to developmental brain defects and the early onset of neurodegenerative
diseases and mental degeneration in Down syndrome (Wegiel et al., 2010).
DYRK1A exists in two splice variants in mammals and rodents. These variants
differ merely in nine amino acids and are equally expressed without any known
functional differences (Kentrup et al., 1996, Guimera et al., 1999). In addition
to the conserved DYRK-homology-box, DYRK1A possesses a N-terminal nuclear
localization sequence (NLS) and a so-called PEST-region, which is proposed to be
relevant for the proteasome dependent protein degradation (Reichsteiner and Rogers,
1996). Furthermore, on the C-terminal site there is a serine rich sequence and a
sequence of 13 histidine residues (fig. 3). This histidine-rich sequence leads DYRK1A
to the nuclear subcompartments called speckles (Alvarez et al., 2003, Salichs et al.,
2009) and can be utilized for immobilized metal ion affinity techniques, e.g. Ni-NTA
purification.
Figure 3: Structure of protein kinase DYRK1A.
ASR: alternative spliced region; NLS: Nuclear localisation sequenz; DH: DYRK-homology-box; Kinase:
kinase domain; PEST: proline-, glutamic acid-, serine- and threonine rich sequence; His: sequence of 13
histidine residues; Ser: sequence with high number of serine residues. The figure is based on Kentrup
et al., 1996.
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To acquire full catalytic activity, DYRK1A has to be phosphorylated on the tyrosine
in position 321 in the activation loop. This autophosphorylation already occurs
during transcription (Kentrup et al., 1996, Himpel et al., 2001, Lochhead et al.,
2005) independent from other domains or cofactors (Göckler et al., 2009) and
stabilizes kinases in a conformation appropriate for substrate binding (Johnson et
al., 1996). However, so far there is no evidence that the dephosphorylation of this
specific activation loop tyrosine can reversibly regulate the catalytic activity of
DYRK1A or any member of the DYRK family (Becker and Sippl, 2011). In contrast,
it was shown that dephosphorylation of tyrosine 321 does not inactivate DYRK1A
(Adayev et al., 2007). Therefore, it can be assumed that phosphorylation of the
activation loop tyrosine is necessary for achieving the active conformation, but not for
retaining it. However, the autophosphorylation on tyrosine residues seems to appear
only in a translational folding intermediate of DYRKs with biochemical properties
different from the mature kinase (Lochhead et al., 2005). This idea is supported by
different kinase inhibitor sensitivities of tyrosine autophosphorylation and substrate
phosphorylation of Drosophila dDYRK2 (Lochhead et al., 2005).
All known studies show that DYRK1A is always catalytically active when isolated
from tissues or cells implying that the activation loop phosphorylation is apparently
constitutive (Becker and Sippl, 2011). Nevertheless, the activity of DYRK1A and
other kinases has to be regulated. There are hints that small changes in expression
levels of DYRK1A lead to distinct phenotypic consequences (Dierssen and de
Lagran, 2006). However, other regulatory mechanisms are also conceivable, e.g. the
association with regulatory proteins such as 14-3-3β (Alvarez et al., 2007) or changes
in subcellular localization (Becker and Sippl, 2011).
Substrates of DYRK1A are phosphorylated at serine or threonine resisdues,
which are located in a consensus sequence (arginine - proline - X - serine/threonine
- proline). After defining this sequence in the year 2000 (Himpel et al., 2000) a
variety of different substrates could be identified reflecting the intricacy of processes
1 INTRODUCTION 8
DYRK1A is involved in. Among these substrates are synaptic proteins such as
dynamin (Chen-Hwang et al., 2002), membrane proteins such as amyloid precursor
protein (Ryoo et al., 2008), transcription factors such as the nuclear factor of activated
T-cells (NFAT) (Arron et al., 2006, Gwack et al., 2006), cell-cycle regulatory proteins
such as p27Kip1 and Cyclin D1 (Chen et al., 2013, Soppa et al., 2014), splicing factors
such as SF3b1 (de Graaf et al., 2006), or nucleotide binding proteins such as septin 4
(Sitz et al., 2008).
In this study the last two mentioned substrates were used for cell based assays.
The splicing factor 3b subunit 1 (SF3b1) is also called SAP155 or SF3b155 and
is a component of the U2 small nuclear ribonucleoprotein particle (snRNP) of
the spliceosome (de Graaf et al., 2006). Positioned in the catalytic center of the
spliceosome, SF3b1 binds the pre-mRNA on both sides of the branch site (Gozani
et al., 1998). The threonine residue on position 434 was identified as predominantly
phosphorylated by DYRK1A in vitro and as a major phosphorylation site of SF3b1
in vivo (de Graaf et al., 2006). The second used substrate is septin 4, a guanosine
triphosphate hydrolase (GTPases) belonging to the group III septin family. It
has been found in neurofibrillary tangles of Alzheimer disease brains as well as
in α-synuclein-positive cytoplasmic inclusions in Parkinson disease brains and is
co-expressed and co-localized with DYRK1A in neocortical neurons (Sitz et al., 2008).
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1.2 Kinase inhibitors
About 30 % of human proteins contain covalently-bound phosphates and it seems
obvious that abnormal phosphorylation is a cause or a consequence of many
diseases, e.g. diabetes, chronic myelogenous leukemia or non-Hodgkins lymphoma
(Lahiry et al., 2010). Protein kinases have now become one of the most important
group of drug targets (Cohen, 2002) and accordingly, there is a growing interest in
developing orally active kinase inhibitors for therapy . Since the first kinase inhibitors
were developed in the early 1980‘s (Cohen, 2002), there are only 15 kinase inhibitors
that have been approved for use in the USA until 2012 (Knapp et al., 2013). However,
nowadays most pharmaceutical companies aim to the development of kinase inhibitors
as therapeutic targets.
1.2.1 Classification of inhibitor modes
Inhibitors are molecules that interact with an enzyme to prevent it from functioning in
a normal manner. In general, inhibitors can be distinguished in two groups: irreversible
inhibitors and reversible inhibitors. In case of irreversible inhibition, usually the
compound modifies an enzyme covalently and often contains reactive functional
groups, which react with amino acid side chains to form strong covalent bonds with
the inhibited enzyme. As a result, irreversible inhibitors specifically alter the active
site of an enzyme, but do not destroy the protein structure. In contrast, reversible
inhibitors bind with non-covalent interactions and can generally be easily removed
(Berg, Tymoszko and Stryer, 2002, section 8.5).
Reversible inhibitors can be further classified into competitive and noncompetitive or
allosteric inhibitors (fig. 4). In case of competitive inhibition, substrate and inhibitor
have an affinity to bind at the same site of the enzyme. A competitive inhibitor
closely resembles the chemical structure and molecular geometry of the substrate and
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Figure 4: Distinction between a competitive and a noncompetitive Inhibitor.
A. Competitive inhibitors bind at the active site and thus prevent the substrate from binding.
B. Noncompetitive or allosteric inhibitors do not prevent the substrate from binding but inhibit the
catalytical activity of the enzyme.
(Berg, Tymoszko and Stryer, fig. 8.15)
both molecules compete for accession to the active site. The inhibitor may interact
with the enzyme at the active site, but without inducing enzyme activity and with
the possibility of being removed from the active site. As a consequence, competitive
inhibitors prevent any substrate molecule from reacting with the enzyme. Therefore,
the inhibition depends on the inhibitor concentration, the substrate concentration,
and the relative affinities of the inhibitor and substrate for the active site. In contrast,
noncompetitive, allosteric inhibitors react either remote from the active site or very
close to it. The net effect of a noncompetitive inhibitor is to change the shape of
the enzyme and thus of the active site so that the substrate can no longer activate
the enzyme. Noncompetitive inhibitors are not influenced by concentrations of the
substrate (Berg, Tymoszko and Stryer, 2002, section 8.5).
Theoretically, kinase inhibitors could react in any of this modes, but virtually all
protein kinase inhibitors that have been developed so far are ATP-competitive (Liu
and Gray, 2006). However, there is one major drawback to these inhibitors. The
ATP-binding pocket is very similar in all protein kinases, and is therefore a limiting
factor in specificity (Ranjitkar et al., 2010). But to improve selectivity, inhibitors are
designed that target pockets bordering the ATP site with groups that have chemical
diversity (Johnson, 2009). Indeed substrate competitive inhibitors would have the
benefit of a higher specificity with less side effects and less toxic effects.
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ATP-binding site kinase inhibitors can be further devided into 2 classes: type I and
type II inhibitors. Structural analyses have revealed five pockets that can be exploited
for binding different chemical groups, which are typical for one class or the other
(Liao, 2007). Figure 5 shows the key residues for contact with CDK2 as well as the five
pockets that have been exploited in drug design exemplary. Type I ATP-binding site
inhibitors can act on the adenine-binding pocket. This pocket is lined by aliphatic and
Figure 5: The ATP and substrate-binding site of CDK2–cyclin A.
Model showing the key residues for binding of the CDK2-cyclin A binding and the five pockets that have
been exploited in drug design. (Johnson, 2009)
aromatic hydrophobic groups and has the potential for two or more hydrogen bonds
with the hinge-region. Often groups with planar geometry bind here given that they
also contain at least one group that can form a hydrogen bond with the hinge-region.
The second possible binding site is the ribose-binding pocket that owns several polar
groups for binding with various chemical groups. Additionally, type I inhibitors can
bind to the so-called ‘p38’ gate keeper pocket. It is guarded by an amino acid residue
known as ‘gatekeeper’. This is often threonine but in some kinases the pocket is
blocked by a more bulky residue, e.g. phenylalanine in CDK2 and DYRK1A. The
hydrophobic pocket is also a possible binding site. It is located below the adenine
pocket and allows targeting by a number of different groups. Type II ATP-binding
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site inhibitors utilize one pocket for binding. The Type II inhibitor pocket is formed
between the C-helix and the activation segment and it accommodates inhibitors that
target the inactive conformation of protein kinases (Johnson, 2009).
In general, both the active and the inactive conformations of the ATP-binding site
can bee used in strategies to generate potent and selective compounds (Johnson,
2009). Nevertheless, the active conformation is preferred because diseases often have
arisen from the activated kinase state, although this strategy often results in a less
specific inhibitor. Additionally, most conventional kinase assays identify inhibitors of
the active kinase conformation. However, targeting the inactive kinase conformation
can result in inhibitors with high specificity, because this conformation is often unique
in comparison to other kinases (Johnson, 2009). One example for a clinically approved
protein-kinase-targeted inhibitor is imatinib. It targets the inactive conformation of
Abl tyrosine kinase, ARG (Abl-related gene), Kit (receptor tyrosine kinase) and
PDGFR (platelet-derived growth factor receptor ) with a high specificity (Liu and
Gray, 2006).
Structure-based drug design is a very important approach to discover novel type-II
kinase inhibitors (Davis et al., 2011), but so far only a few inactive kinase structures
have been solved and the structural information about inactive conformations is still
lacking for a large number of kinases (Marsden and Knapp, 2008). Additionally, the
complexity of signaling pathways and the cross-talk between pathways is complicated
and therefore it is difficult to engineer a specific inhibitor without interfering with
other pathways and cell functions.
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1.2.2 Harmine: a potent DYRK1A inhibitor
Harmine is a β-carboline alkaloid originally isolated from the South American vine
Banisteriopsis caapi but also found in Peganum harmala, a wild rue widely distributed
in northern Africa, the Middle East and the southern Asian region. It is a serotonin
analogue with only 212 Da (fig. 6) and was found actually as monoamine oxidase
A (MAO A) inhibitor with a half maximal inhibitory concentration (IC50) of 5 nM
(Kim et al., 1997) .
Figure 6: Chemical structure of harmine.
MAO A catalyzes the oxidative deamination of various biogenic amines in the brain
and peripheral tissues by producing hydrogen peroxide. It is located in the outer
mitochondrial membrane and preferentially oxidizes serotonin, norepinephrine, and
dopamine (Shih et al., 1999). Thus, dysfunctions of MAO A are involved in a number
of neuropsychiatric disorders, such as depression, social anxiety, autism, and attention
deficit hyperactivity disorder (Wu et al., 2009).
In 2007, a screening against a panel of 69 kinases identified harmine as potent
DYRK1A inhibitor (Bain et al., 2007). Comparative in vitro assays revealed that
harmine inhibited substrate phosphorylation by DYRK1A more potently than by the
other tested kinase family members (Göckler et al., 2009). The half maximal inhibitory
concentration for DYRK1A was determined at 33 nM, while the closely related kinase
DYRK1B showed an IC50 of 166 nM and the more distant members DYRK2, DYRK3
and DYRK4 1.9 µM, 0.8 µM and 80 µM, respectively (Göckler et al., 2009; Smith et al.,
2012). Additionally, cell culture assays confirmed the potency of harmine for DYRK1A
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(IC50 = 48 nM, Göckler et al., 2009). The same study revealed that concentrations up
to 1 µM only cause minimal toxicity in viability assays with HeLa and HEK293 cells.
It is also known that harmine has inhibitory potency for the DYRK related kinase
CLK1 (IC50 = 27 nM; Grabher et al., 2012) and the serine/threonine kinase haspin
(IC50 = 590 nM; Cuny et al., 2012). To date, several other targets for harmine have
been discovered by high throughput screenings or kinase profiling screenings, but in
general much higher concentrations of harmine are needed for inhibitory effects on
other kinases (reviewed by Patel et al., 2012).
The crystal structure of the DYRK1A ⁄ harmine complex (Ogawa et al., 2010) proved
the involvement of specific amino acids in binding modeled by Becker and Sippl in
2011. Harmine binds to the ATP-binding pocket and interacts with the backbone
NH of methionine on position 240 of the hinge-region as well as with the conserved
lysine on position 188 by forming two hydrogen bonds (fig. 7). Furthermore, the
structure of the DYRK1A ⁄ harmine complex suggests that the accessible volume
of the ATP-binding pocket is able to accommodate substituents at the β-carboline
structure (Becker and Sippl, 2011). As a consequence, it is likely that harmine can be
modified into an optimized DYRK1A inhibitor.
Figure 7: Model of the DYRK1A/harmine complex.
Close-up of DYRK1A ATP-binding pocket with docked harmine. Only the interacting amino acid residues
are displayed. Harmine is coloured pink and the formed hydrogen bonds to M240 and K188 are shown as
dashed lines (Becker and Sippl, 2011).
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1.2.3 Other known DYRK1A inhibitors
There are various chemical compounds reported as specific DYRK1A inhibitors with
different selectivities. In this work some of these known DYRK1A inhibitors will be
introduced, to give a short overview over the inhibitors that seem most interesting.
In 2007, Bain and co-workers investigated some harmine derivatives regarding their
inhibitory effects on DYRK1A. They tested harmane, harmalol and harmaline against
a panel of 69 kinases and defined remaining activities of 44%, 67% and 29%,
respectively, in presence of 1µM of the certain inhibitor. In conclusion, none of
these derivatives show a comparable inhibitory potency on DYRK1A as harmine
(4% remaining kinase activity). In 2011, Frost and co-workers examined the inhibition
of tau phosphorylation after treatment with harmol, harmane, norharmane, harmaline
and 9-ethyl harmine. In this study 9-ethyl harmine and harmol were identified as
most potent harmine derivatives with IC50 values of 400 nM and 90 nM, respectively.
Furthermore, harmol, harmane and harmaline are also known to inhibit MAO A
(McKenna et al., 1984), as it is also known for harmine.
Epigallocatechin gallate (EGCG) is a natural polyphenolic compound that represents
the major component of tea, especially of green tea (fig. 8). EGCG is reported to
have antibacterial and antiviral effects as well as antioxidative and anti-inflammatory
properties (reviewed in Smith et al., 2012). In 2003, EGCG was identified as an
inhibitor of DYRK1A with an in vitro IC50 value of 330 nM (Bain et al., 2003).
Kinetic analysis in NIH3T3 cells with a specific DYRK1A mutant indicated that this
catechin functions as a noncompetitive inhibitor against ATP (Adayev et al., 2006).
This study also suggests that EGCG inactivates DYRK1A by binding to a distinct
site on this kinase with the effect of inhibiting the catalysis. EGCG is also reported
to be able to cross the blood-brain barrier (Lin et al., 2007), but even after excessive
dosing just very low or undetectable levels of EGCG have been found in rat brains
(Lin et al., 2007; Zini et al., 2006) so this property of EGCG is disputed.
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Figure 8: Structure of Epigallocatechin gallate (EGCG).
TBB (4,5,6,7-tetrabromo-1H-benzotriazole) has been developed originally as a
cell-permeable, selective inhibitor of casein kinase-2 (Sarno et al., 2001). However,
in 2008 a selectivity profile screening revealed that TBB also inhibits DYRK1A with
an IC50 value of 4.36 µM (Pagano et al., 2008). In addition, the related kinases DYRK2
(IC50 = 0.99 µM), DYRK3 (IC50 = 5,3 µM), HIPK2 (IC50 = 5,3 µM), HIPK3 (IC50
= 4,9 µM) as well as PIM3 (IC50 = 0.86 µM) were discovered as further targets of
TBB.
TG003 is a benzothiazole compound and is primarily found as a cell permeable CLK1
and CLK4 inhibitor with 20 nM and 15 nM potency, respectively [Muraki et al., 2004).
However, more comprehensive profiling of this compound revealed that it is also a
strong inhibitor for all CLK family members except for CLK3, but among others
it is also cross reactive with DYRK1A, DYRK1B, and the proto-oncogene proviral
integration site for moloney murine leukemia virus (PIM) kinases 1 and 3 (Mott et al.,
2009). TG003 shows a half maximal inhibitory concentration for DYRK1A of 12 nM
(Mott et al., 2009) and 930 nM (Ogawa et al., 2010), depending on the respective
assay conditions.
In 2010, the benzothiazole derivative INDY (inhibitor of DYRK) was characterized
as potent DYRK1A inhibitor with an IC50 value of 240 nM (Ogawa et al., 2010). It
shares the benzothiazole structure with TG003, but shows a more potent inhibitory
activity towards DYRK1A. INDY also inhibits the members DYRK 1B, 2 and 4
of the DYRK family and likewise the related kinases CKL1 and CLK2 as well as
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PIM1, but no inhibitory activity could be measured towards MAO A (Ogawa et al.,
2010). Additionally, this study determined how INDY inhibits DYRK1A and therefor
the DYRK1A/INDY complex was co-crystallized (fig. 9). INDY forms hydrogen
bonds with lysine on position 188 and with leucine on position 241 within the ATP
binding-pocket of DYRK1A.
Figure 9: Structures of TG003, INDY and the DYRK1A/INDY complex.
A, Chemical structure of the benzothiazole TG003.
B, Chemical structure of the benzothiazole derivate INDY.
C, Stereo view of the inhibitor-binding site of the DYRK1A/INDY complex with surrounding amino acids.
Hydrogen bonds are depicted as red dotted lines (Ogawa et al., 2010 / PDB accession 3ANQ.)
Leucettamine B is a natural compound, which was isolated in 1993 from the
sponge Leucetta microraphis Haeckel (Calcarea). In 2011 it was discovered as
promising compound to inhibit DYRKs and CLKs and the half maximal inhibitory
concentrations were determined as 2,8 µM for DYRK1A and 400 nM for CLK1
(Debdab et al., 2011). Additionally, the leucettamine B analogue leucettine L41 was
synthesized and characterized by Tahtouh and co-workers in 2012 (fig. 10). L41 shows
an IC50 value of 12 nM for DYRK1A and the co-crystal structure determined the
expected binding of L41 at the ATP binding site of DYRK1A and a hydrogen bond
with the leucine on position 241 (Tahtouh et al., 2012).
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Figure 10: Structure of leucettamine B and leucettine L41.
from Tahtouh et al., 2012.
Another reported DYRK1A inhibitor is dNBC (denitro NBC), a condensed
polyphenolic compound derived from the scaffold of cumarin (Sarno et al., 2012).
This compound was screened against a panel of 115 kinases and revealed a high
inhibitory potency against DYRK1A with an IC50 value of 600 nM. It interacts with
both the hinge region and the phosphate binding region of the ATP binding site and
is proposed to form hydrogen bonds with the lysine on position 188 and the leucine
on position 241 in the hinge-region (Sarno et al., 2012).
KHCB19 is a dichloroindolyl enaminonitrile, which was discovered as a potent
and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1,
CLK4) (Fedorov et al., 2011). The half maximal inhibitory concentrations for CLK1
and DYRK1A were determined at 20 nM and 55 nM, respectively. NIH54 is a
dichloroindolyl enaminonitrile related to KH-CB19, but with lower affinity for CLK3
(Walte et al., 2013).
In 2012, a study examining the role of β-carboline derivatives as haspin kinase
inhibitors was carried out and a compound named 42 was introduced with an IC50
value of 100 nM for haspin (Cuny et al., 2012). A screening against a panel of 292
kinases revealed that also DYRK1A and other DYRK family members as well as
some protein kinases of the CMGC group are likewise inhibited by more than 90%.
However, only the IC50 value for DYRK2 was calculated, which was defined to 15 µM
(Cuny et al., 2012).
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Recently another new DYRK inhibitor was published. The 2,4-bisheterocyclic
substituted thiophene compound 48 was actually designed as DYRK1B inhibitor with
an IC50 value of 70 nM (Schmitt et al., 2014). But also IC50 values for DYRK1A,
DYRK2 and CLK1 were determined with 100 nM, 40 nM and 110 nM, respectively.
Additionally, this study evaluated the metabolic stability of compound 48 in rat liver
microsomes and figured out that this substituted thiophene compound displayed a
slightly more metabolic stability in comparison to harmine (Schmitt et al., 2014).
1.3 Aim of the study
Harmine is probably one of the most potent and selective inhibitors of DYRK1A
presently available and it has been used in several studies to investigate DYRK1A
(reviewed in Becker and Sippl, 2001). Nevertheless, its inhibitory effect on MAO A
limits the use of this β-carboline alkaloid as chemical probe in tissue experiments or
animals and as a therapeutic agent. The present study aimed to develop a harmine
analogue to get an inhibitor usable as chemical probe to investigate the functions of
DYRK1A specifically in biological systems, cell assays and animal experiments. This is
not always possible with knock-out organisms, so the new β-carboline alkaloid should
have a potency and selectivity towards DYRK1A comparable or better than harmine,
but without inhibitory effects on MAO A. Already known inhibitors fail because of
their poor ability to enter cells. Contemporary, also the decrease of CLK1 inhibition
was desired but not high-profiled. The rather small molecule size of 212 Da seems to
be favorable to use harmine as a lead structure for an optimized DYRK1A inhibitor.
Known crystal structures of the DYRK1A/harmine complex and docking models were
used.
The second objective was to examine the mechanism of dual specificity kinase
activity in mammalian DYRK1A. The current model of the mechanism of
tyrosine autophosphorylation in the DYRK family is based on a study of the
Drosophila DYRKs dDYRK2 and MNB (Lochhead et al., 2005), but has not been
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verified for DYRK1A yet. However, our group has recently found that tyrosine
autophosphorylation of DYRK1A is an intrinsic capacity of the catalytic domain and
does not depend on the presence of chaperones (Göckler et al., 2009). In particular,
this study was designed to investigate whether tyrosine phosphorylation is a strictly
co-translational event or whether it can still take place in mature DYRKs. Another
aim was to examine the potential role of the regulatory tyrosine in the activation
loop as only target site of DYRK tyrosine kinase activity and to study the potential
of inhibitors to differentially target the tyrosine kinase form and the mature serine/
threonine-specific conformation of DYRK1A. According to Lochhead et al. (2005) it
should be possible to find a specific and irreversible inhibitor for DYRKs.
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2 Material and methods
2.1 Chemicals and drugs
All chemicals were obtained from Sigma-Aldrich Co. LLC. (Munich, Germany), Merck
Eurolab GmbH / VWR (Darmstadt, Germany) or AppliChem GmbH (Darmstadt,
Germany).
The following kinase inhibitors were obtained commercially: staurosporine (Enzo
Life Sciences, Lörrach, Germany), TG003 (Sigma Aldrich, Taufkirchen, Germany),
harmine (Fluka, Buchs, Switzerland), INDY (Merck Millipore, Darmstadt, Germany),
leucettine L41 (Adipogen via BIOMOL GmbH, Hamburg, Germany), TBB and
5-Iodotubercidin (Tocris Bioscience, Minneapolis, MN, USA). KH-CB19 was
synthesized as described previously (Fedorov et al., 2011). Synthesis of studied
harmine derivatives and some other used compounds were described in the dissertation
of Anne Wurzlbauer, 2013. Inhibitors were dissolved in dimethylsulfoxide (DMSO) to
create a 1 mM stock solution, except harmine which was dissolved in ethanol as
described previously (Göckler et al., 2009). Further dilutions of the inhibitors were
prepared in water to get a final concentration of 1% DMSO in kinase activity assays,
3% DMSO in in vitro translation reactions or 0.05% DMSO in cell assays.
2.2 Equipment and Software
2.2.1 Equipment
1. Agarose gel electrophoresis chamber:
Agagel Mini, Biometra (Göttingen, Germany)
2. Centrifuge:
Sigma 112 table separator, Sigma (Osterode, Germany)
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Centrifuge 5417R, Eppendorf (Hamburg, Germany)
Heraeus Multifuge 3SR+, Thermo Scientific (Langenselbold, Germany)
AvantiTMJ-25 Ultracentrifuge, Beckman CoulterTM (Fullerton, CA, USA)
3. Fluorescence microscope:
LSM 710, Carl Zeiss MicroImaging GmbH (Jena, Germany)
Axiovert 200M, Carl Zeiss MicroImaging GmbH (Jena, Germany)
4. PCR:
Primus 96plus, MWG Biotech (Ebersberg, Germany)
5. SDS-PAGE equipment:
Minigel Twin G42, Biometra (Göttingen, Germany)
6. Western blotting equipment:
TE22 Mini Transfer Tank, Hoefer (Holliston, MA, USA)
7. Western blotting detection:
LAS-3000 Imager, Fujifilm (Düsseldorf, Germany)
8. 96 wells platte reader:
Lamda E, MWG Biotech (Ebersberg, Germany)
2.2.2 Software
1. Statistic software:
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA)
JMP 9 (SAS Institute, Cary, NC, USA)
2. Densitometric analysis:
AIDA Image analyzer 3.52 (Raytest, Straubenhardt, Germany)
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2.3 Antibodies
Mouse monoclonal antibodies against phosphotyrosine (PY99; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), against SF3B1 (SAP155; MBL, Nagoya,
Aichi, Japan) and against FLAG-tag (FLAG® BioM2, Sigma Aldrich Chemie
GmbH, München, Germany) were purchased commercially, as well as Strep-Tactin
horseradish peroxidase conjugate (IBA BioTAGnology, Göttingen, Germany) and
goat antibody against GFP (Rockland Immunochemicals Inc., Gilbertsville, PA,
USA). A sheep DYRK1A antibody was kindly provided by Sir Philip Cohen (MRC
Protein Phosphorylation Unit, Dundee, UK). The rabbit antibody used in the kinase
assays for detecting phosphorylated Thr434 in SF3B1 (pT434) has been described
previously by de Graaf et al. 2006. The rabbit polyclonal phospho-specific antibody
for DYRK1A phosphorylated at Ser748 (anti-pS748) was generated by immunizing
rabbits with the phosphopeptide GADREEpSPMTGVC (pS is a phospho-Ser residue)
conjugated to LPH (hemocyanine from Limulus Polyphemus). Custom immunization
and antibody purification was performed by BioGenes, Berlin, Germany (see
dissertation of C. Papadopoulos, 2011). All secondary antibodies were horseradish
peroxidase-coupled and used 1:5000.
2.4 Plasmids
Expression constructs for T7 polymerase-driven bacterial expression contained the
Strep-tag II sequence (MAW- SHPQFEK) N-terminal of the catalytic domain of
the kinases of interest in the vector pET28a. DYRK1A cDNA was also cloned into
pBEN-SGC (kind gift from O. Gileadi, Structural Genomics Consortium, Oxford, UK)
to produce a fusion protein with an N-terminal streptavidin binding peptide (SBP)
tag and as indicated additionally a C-terminal sequence segment derived from splicing
factor 3B1 (SF3B1). A detailed description of the expression constructs was reported
previously (Walte et al., 2013). Mammalian expression plasmids for the DYRKs and
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CLK3 have also been described previously (Papadopoulos et al., 2011; Becker et al.,
1998). Point mutants of DYRK1A and DYRK2 were created by DpnI-mediated site
directed mutagenesis. The GFP-HIPK2 expression plasmid was kindly provided by
M. L. Schmitz (Justus-Liebig-University Giessen, Germany).
Bacterial expression plasmids for GST-DYRK1A-∆C and GST-DYRK2 (Himpel
et al. 2000; Becker et al. 1998), as well as for GST-DYRK1Bcat and CLK1cat
expression vectors (Walte et al., 2013) have been described earlier. To generate the
GST-HIPK2cat expression vector, human cDNA encoding the catalytic domain of
HIPK2 (amino acids 180-533 of the reference sequence NP_00110671) was inserted
into pGEX-2TK vector via engineered BamHI and EcoRI sites. To produce the
recombinant kinases for the in vitro assays bacterial expression plasmids were
expressed in E. coli culture logarithmically growing for three hours at 26°C. GST
fusion proteins were partially purified by affinity adsorption to glutathione-sepharose
and stored in the elution buffer (50 mM Tris-HCl pH 8.0, 10 mM reduced glutathione)
at -80°C until use.
2.5 Expression in E. coli
GST-fused kinase constructs were transformed into E. coli BL21 (DE3) and
1 mL LB medium with 30 µg/mL kanamycin were inoculated with 50 µL of an
overnight culture and incubated at 37 °C, 230 rpm. Expression in logarithmically
growing E. coli culture was performed for three hours at 37°C (GST-DYRK1A-∆C
and GST-DYRK2), over night at 28°C (GST-CLK1cat) or at room temperature
(GST-DYRK1Bcat). When cultures reached an OD of 0.6-0.8, they were induced
with 0.1 mM isopropyl-b-D-thiogalactopyranoside. After two hours, 100 µL samples
were taken and cells were harvested by centrifugation. Each pellet was lysed in 10 µL
Lämmli sample buffer and directly subjected to Western blot analysis.
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2.6 Expression in vitro
For in vitro expression the PURExpress In Vitro Protein Synthesis Kit from New
England Biolabs (Beverley, MA, USA) was used. Therefor 100 ng of the respective
kinase constructs were used in a total volume of 10 µL and expressed at 37 °C for
1 h or the time indicated in each experiment. If indicated, the respective inhibitor
concentration was diluted before adding to not exceed a final DMSO concentration
of 3%. Likewise additionally, the substrate SF3B1-NT-His6 was added as mentioned
in the respective experiment. If indicated, translation was stopped with 30 µg/mL
kanamycin and 0.89 mg/mL RNAse A and 15 µL Lämmli sample buffer with 5 mM
EDTA was added. Samples were directly subjected to Western blot analysis or stored
at -20°C until use.
2.7 Kinase activity assays
2.7.1 In vitro activity assay
To measure the effect of kinase inhibitors on in vitro expressed DYRK1A
(fig. 29), PURExpress® reaction mixes with wild-type pET-ST2-DYRK1A or
pET-ST2-DYRK1A-Y321F were diluted 1:60 with kinase buffer (25 mM Hepes
pH 7.4, 0.5 mM dithiothreitol, 5 mM MgCl2) and then incubated for 5 min at 37
°C with 2 µg SF3B1-NT-His6 and 500 µM ATP in the presence of the respective
compounds. Phosphorylation of SF3B1 on threonine on position 434 was determined
by immunoblot analysis with the help of the phosphospecific antibody Thr434.
2.7.2 Kinase-GLO assay
Inhibitory effects of all new β-carbolines against GST-DYRK1A-∆C,
GST-DYRK1Bcat, GST-DYRK2, GST-CLK1cat or GST-HIPK2cat were determined
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by using the Kinase-GLO® Luminescent Kinase Assay from Promega. Assays were
performed in a total volume of 10 µL in kinase-buffer (25 mM Hepes pH 7.4, 0.5
mM DTT, 5 mM MgCl2, 5 µM ATP) with appropriate peptide substrates (20
µM DYRKtide for the DYRKs and 100 µM for HIPK2, RRRFRPASPLRGPPK, or
100 µM RStide for CLK1, GRSRSRSRSR). Assays were started with this amount of a
kinase preparation that consumed approximately 90% of the ATP in the assay (linear
range of the kinase titration curve). The reactions were run at room temperature
for 30 min before 10 µL Kinase-Glo Reagent was added. After incubation at room
temperature for additional 10 min, luminescence was recorded for 1 sec.
2.7.3 Radioactive activity assay
Radioactive activity assays were used to determine IC50 values of selected compounds
for the inhibition of DYRK1A. GST-DYRK1A-∆C was incubated with 100 µM
DYRKtide, 100 µM ATP, 5 µCu [γ-33P]-ATP and the indicated compound
concentration in kinase buffer (25 mM Hepes, pH 7.4, 0.5 mM DTT, 5 mM MgCl2)
for 5 min at 30°C. Each sample was assayed in triplicate. Reactions were stopped
by pipetting onto P81 phosphocellulose paper (Whatman) and immediate immersion
in 5% phosphoric acid. Phosphocellulose paper were washed at least 5 times and
radioactivity was measured by counting in 5ml Rotiszint® eco plus (Carl Roth,
Karlsruhe, Germany) (Hastie et al., 2006). Background control was subtracted from all
samples and the sample without a compound was set as 100% kinase activity to relate
compound treated samples to this value. The half maximal inhibitory concentrations
were calculated with the help of the GraphPad Prism 5.0 program after automatical
outlier elimination.
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2.7.4 AnnH75 kinome profiling
Profiling of AnnH75 against a panel of 300 wild type kinases was performed by
ProQinase (Freiburg, Germany) using a radiometric protein kinase assay in a duplicate
measurement. Gini coefficients were calculated by applying the Microsoft Excel
spreadsheet by Graczyk P.P., 2007.
2.7.5 MAO A assay
The inhibitory effect against monoamine oxidase A (MAO-A) was determined by
using the MAO-GLO™ Assay System from Promega (Mannheim, Germany). The
assay was performed according to the manufacturer’s instructions with 12 µU human
recombinant MAO-A (Promega, Mannheim, Germany) and 25 µM MAO-A substrate
in a total volume of 20 µL.
2.7.6 ADP-GLO assay
The activities of purified SBP-DYRK1Acat wild type and SBP-DYRK1Acat Y321F
point mutant were determined after in vitro translation in presence of 5-Iodotubercidin
or staurosporine by using the ADP-GLO™ Kinase Assay from Promega. Eluted protein
kinases were pre-incubated for 15 min or 30 min at 30°C in a total volume of 40 µL in
kinase-buffer (25 mM Hepes pH 7.4, 0.5 mM DTT, 5 mM MgCl2, 100 µM ATP) with
100 µM DYRKtide as substrate. An 20 µL aliquot of pre-incubated protein kinase
was added to 20 µL ADP-Glo reagent and incubated at room temperature for 40 min
before 40 µL detection reagent was added. After incubation at room temperature for
additional 40 min, luminescence was recorded for 1 sec.
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2.7.7 Autophosphorylation assay
After in vitro expression in the presence of 30 µM staurosporine, 10 µL samples were
diluted 100-fold with DYRK kinase buffer (25 mM Hepes pH 7.0, 0.5 mM MgCl2, 0.5
mM dithiothreitol) and incubated with 1 mM ATP. The reaction was stopped at the
indicated time points with 10 mM EDTA, 4 volumes of ice-cold acetone were added
and the samples were stored at 20 °C for 1 h. After centrifugation, the pellets were
dissolved in Lämmli’s sample buffer and subjected to Western blotting.
2.8 Cell culture
All cell culture workings were carried out on a clean bench. All used cell lines were
cultured in the respective medium at 37°C, 5% CO2 and 70% - 80% atmospheric
humidity in 75 cm2 cell culture flasks (Sarstedt, Nümbrecht, Germany).
2.8.1 HeLa cells
In 1951, epithelial cells were removed from a cervical carcinoma of the Afro-American
woman Henrietta Lacks, who became infected with the papilloma virus 18 (HPV18).
These cells were called HeLa cells and they are the first human cultivable cell line (Gey
et al., 1952, Scherer et al., 1953). HeLa cells were cultured in Quantum 101 medium
for HeLa Cells with L-glutamine (PAA Laboratories GmbH, Pasching, Austria) or
Dulbecco’s modified Eagle medium (DMEM) high glucose [4.5 g/L], with L-glutamine
and 10% added fetal bovine serum (both from PAA Laboratories GmbH, Pasching,
Austria). Medium was changed every 2-3 days and when cells were confluent, medium
was removed, cells washed with PBS (140 mM NaCl, 3 mM KCl, 8 mM Na2HPO4,
1.8 mM KH2PO4) and to peel cells away they are incubated with 1x trypsin-EDTA
in PBS for 2 min at 37°C. This reaction was stopped by addition of 10 mL medium
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and cells were resuspended 1:10 for further cultivation or seeded for an experiment in
10 cm tissue culture dishes (Sarstedt, Nümbrecht, Germany).
2.8.2 HEK293-TetON-GFP-DYRK1A cells
HEK293 cells are human embryonic kidney cells, which are cultivated since the
late 1970s (Graham et al., 1977). This human cell line was transformed with
adenovirus type 5 DNA and thereby immortalized. The HEK293 subclone used in
the present study was stably transfected with an expression vector for GFP fusion
protein of DYRK1A, which is under the control of a tetracycline-regulated promoter
(described in Sitz et al., 2008). For expression 2 µg/mL doxycyclin was used and
HEK293-TetON-GFP-DYRK1A cells were cultivated in DMEM high glucose [4.5 g/L],
with L-glutamine and 10% added fetal bovine serum supplemented with 100 units/ml
penicillin and 100 µg/ml streptomycin.
2.8.3 PC12-TetON-GFP-DYRK1A cells
PC12 cells are neuronal like cells, which derived from a pheochromocytoma of the rat
adrenal medulla (Greene and Tischler, 1976). PC12 cells are also stably transfected
with an expression vector for GFP fusion protein of DYRK1A under the control
of a tetracycline-regulated promoter (Sitz et al. 2008). For expression 2 µg/mL
doxycyclin was used and PC12-TetON-GFP-DYRK1A cells were cultivated in DMEM
High Glucose containing 10% horse serum (PAA Laboratories GmbH, Pasching,
Austria), 5% fetal bovine serum and 25mMHEPES (Sigma-Aldrich Co. LLC., Munich,
Germany).
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2.8.4 SH-SY5Y cells
SH-SY5Y cells are human neuroblast-like subclone of cells isolated from bone marrow
biopsy taken from a four year-old girl (Biedler et al., 1973). SH-SY5Y cells were
cultivated in DMEM high glucose [4.5 g/L], with L-glutamine and 10% added fetal
bovine serum supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin.
2.8.5 Transient transfection
Transient transfections were performed by using FuGENE™ HD Transfection Reagent
(Roche Roche Diagnostics Deutschland GmbH, Mannheim, Germany) according to
the manufacturer’s instructions. Therefor 125000 cells/mL were mixed with 500 ng of
the respective DNA and incubated for 5 minutes at room temperature. Then the 2.5
fold volume of FuGENE™ HD Transfection Reagent was supplemented and after 15
minutes incubation at room temperature cells were added. This mix was shaken for
5 minutes at 300 rpm, after medium addition once again shaken and distributed on
plates. After 24 hours cells were washed and if indicated treated with the respective
inhibitor for 20 hours.
2.8.6 Cell viability assay
Cytotoxicity of selected compounds was evaluated in HeLa, PC12 and SH-SY5Y
cells after 3 days of incubation with the respective compound concentration by
using a tetrazolium dye assay (XTT assay, AppliChem GmbH, Darmstadt, Germany)
following the manufacturer’s instructions.
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2.9 Protein biochemistry
2.9.1 Protein isolation and purification from cells
Depending on the objective of the respective experiment, used cell material was lysed
with one of the following methods and subsequently kinases were purified with the
requested method.
2.9.1.1 SDS lysis
SDS lysis was used when whole cell lysates were directly subjected to SDS
polyacrylamide gel electrophoresis. All steps were carried out on ice. The medium was
removed and cells were washed with ice cold PBS. Afterwards, cells were lysed with
120 µL boiling SDS lysis buffer (20 mM Tris HCl pH 7.4, 1% SDS) and cells were
deattached using a scraper. The cell lysate was transferred to an Eppendorf reaction
tube and boiled for 5 minutes in a water bath. After 30 seconds of sonification,
lysates were centrifuged for 5 minutes at 4°C with 14000 rpm. The supernatant was
transferred to another reaction tube and stored at -20°C until further use.
2.9.1.2 Non-denaturing cell lysis
Non-denaturing cell lysis was used when expressed kinases were purified by
GFP-Trap magnetic beads and/or further applied to kinase activity assays. Therefor
medium was removed and cells were washed with ice cold PBS. After addition of
1 mL native lysis buffer (50 mM TrisCl pH 7.5, 150 mM NaCl, 15 % glycerol, 1
mM EDTA, 1 mM NaF, 0.5 % Igepal CA-630, supplemented with 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride and 10 µg/mL each of aprotinin, pepstatin
and leupeptin), tissue culture dishes were shaken for 20 minutes on ice. Cells were
collected using a scraper and cell lysates were transferred to an Eppendorf reaction
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tube. After 2 x 15 seconds of sonification, lysates were cleared by centrifugation for 3
minutes at 4°C with maximum revolutions. The supernatant containing the proteins
was used for GFP-Trap magnetic beads purification and/or kinase activity assays.
2.9.1.3 GFP-Trap magnetic beads purification
GFP-Trap magnetic beads are paramagnetic particles bound to single domain
camelid antibodies directed against GFP (ChromoTek, Martinsried, Germany).
These paramagnetic particles can be isolated from a suspension using a magnet
and the proteins precipitated of a solution. This purification was used to purify the
requested proteins and if indicated to apply them to kinase activity assays. Therefor
supernatant of native cell lysates were incubated with 15 µL GFP-Trap magnetic
beads for 1 h at 4 °C in an overhead shaker. The beads were washed three times
with washing buffer (50 mM TrisCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1%
Igepal CA-630) and resuspended in kinase buffer for further kinase activity assays or
dissolved in Lämmli’s sample buffer for direct subjection to SDS polyacrylamide gel
electrophoresis.
2.9.2 Phosphatase treatment
For treatment with the calf intestinal phosphatase (NEB New England Biolabs GmbH,
Frankfurt a.M., Germany), pET-ST2-DYRK1A constructs were in vitro translated for
2 hours at 37°C and subsequently divided into two samples. One sample was incubated
with 20 units of CIP in CIP buffer (NEB New England Biolabs GmbH, Frankfurt a.M.,
Germany) for one hour at 37°C, the other sample was incubated just with CIP buffer as
control. To inactivate the used phosphatase, all samples were incubated for 20 minutes
at 65°C and then dissolved in Lämmli’s sample buffer for direct subjection to SDS
polyacrylamide gel electrophoresis.
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2.9.3 SDS polyacrylamide gel electrophoresis
SDS polyacrylamide gel electrophoresis (SDS PAGE) is used for separation of whole
cell lysates or purified kinases. Polyacrylamide gels were used with a percentage
content of 8%. All samples were dissolved in Lämmli’s sample buffer and boiled for
5 minutes at 96°C. Likewise, the biotinylated protein ladder (CST Cell Signaling
Technology, Danvers, MA, USA) was boiled and afterwards centrifuged briefly.
Electrophoresis was run with a current of 10 mA for each stacking gel and 20 mA
for each running gel.
2.9.4 Western blotting
Samples were resolved by SDS-PAGE and blotted onto nitrocellulose membranes
(Whatman, Dassel, Germany). The membranes were blocked with 3% BSA in TBS-T
(20 mM TrisCl (pH 7.6), 137 mM NaCl containing 0.1% Tween-20) and incubated with
primary antibodies or Strep-Tactin HRP conjugate over night at 4°C or 2h at room
temperature, respectively. After washing with TBS-T, membranes were incubated for
one hour at room temperature with the corresponding secondary antibody in 5%
milk in TBS-T and additionally anti-biotin for marker detection. Chemiluminescence
signals were detected using a LAS-3000 CCD imaging system and band intensities
were evaluated densitometrically with the help of the AIDA IMAGE ANALYZER 3.52
software (Raytest, Straubenhardt, Germany). Anti-phosphotyrosine immunoreactivity
was determined as a quantitative estimate of tyrosine phosphorylation. To compare
data obtained in separate Western blots in independent experiments, relative
anti-phosphotyrosine immunoreactivity was calculated by division of the total protein
signal of each lane and normalized to the untreated sample included in every blot.
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2.10 Statistics
Statistical analysis was performed with GraphPad Prism5 (GraphPad Software,
Inc., La Jolla, USA) or JMP9 (SAS Institute, Cary, NC, USA). In case of
non-linear regression, i.e. concentration-response curves or comprised 4-parameter
logistic regression, parameters were compared by the extra-sum-of-square F-test.
Data in multiple comparisons were compared by one-way ANOVA followed by
Dunnett’s test, if data were homoscedat. Therefore, variances were analyzed by
the Brown-Forsythe test and normal distribution of residues was checked by the
Shapiro-Wilk test. If needed and possible, percentage data were arcsin transformed
to achieve homoscedasticity. If data were heteroscedat, even after transformation,
groups were compared with the Steel test against the control group (harmine)
non-parametrically.
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3 Results
3.1 Novel harmine analogues
3.1.1 Selectivity of novel harmine analogues as DYRK1A inhibitors
Harmine, probably one of the most potent and selective inhibitors of DYRK1A, was
used as a lead substance for the design and synthesis of a panel of new β-carboline
analogues in order to develop a new DYRK1A inhibitor without MAO A inhibitory
activity. All new compounds were synthesized after corporate arrangement with the
center for drug research in the department of pharmacy by collaborators of Prof.
Dr. Franz Bracher in Munich. Procedures for the synthesis of all compounds are
summarized in the dissertation of Anne Wurzlbauer, 2013. Overall, a series of 75
compounds was tested on DYRK1A and some related protein kinases, e.g. CLK1
as known DYRK1A inhibitor off-target or HIPK2. Additionally, all compounds were
tested regarding their inhibitory effect on the used assay itself, without any detectible
inhibition on this system.
First, all compounds were tested on their inhibitory effect against DYRK1A. Only
those compounds were further tested that showed a comparable or better inhibition
of DYRK1A than harmine, i.e. a compound had to inhibit DYRK1A by more than
60% at a concentration of 1 µM. This criterion was complied by 37 compounds.
Table 1 shows these inhibitors in an alphabetic enumeration in comparison to
the lead structure harmine (for a list of synthesized β-carbiline compounds see
table S1 in the supplement). The most potent β-carboline analogues in this series
were AnnH22, AnnH24, AnnH26_5, AnnH27, AnnH31, AnnH43, AnnH44, AnnH63,
AnnH70, AnnH73 and AnnH75, which inhibited DYRK1A by 90% and more.
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Table 1: Tested compounds with inhibitory effect on DYRK1A.
Kinase-GLO assay was performed as described in the experimental procedures with 1 µM of the respective
compound. The average of residual activity of DYRK1A is depicted as percentage of the respective number
of performed experiments. Additionally, the standard deviation for harmine is specified, because it was
larger than for the other tested compounds.
name of compound residual activity number of experiments
of DYRK1A [%]
harmine 27 ± 13 23
AnnH1 24.5 2
AnnH3 26 2
AnnH12 30 3
AnnH18_5 27 3
AnnH21 14.5 3
AnnH22 3 3
AnnH24 10 3
AnnH25 40 3
AnnH26_5 2 3
AnnH27 4 3
AnnH28_2 36 3
AnnH31 8 9
AnnH32_2 12 3
AnnH38 12 3
AnnH40 40 2
AnnH42 22 3
AnnH43 5 5
AnnH44 5 5
AnnH52 36 3
AnnH53 33 3
AnnH57 33 3
AnnH63 6 6
AnnH66 26 3
AnnH67 17 3
AnnH69 17 3
AnnH70 6 3
AnnH73 6 3
AnnH74 12 3
AnnH75 10 3
AnnH76 35 3
AnnH89 37 3
AnnH90 36 3
AnnHT5 28 3
harmol 18 3
KH-CB19T 12 6
NIH54 19 5
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A number of these interesting compounds were chosen for further characterization
and the IC50 values for DYRK1A inhibition were determined using the Kinase-GLO
assay (fig. 11). This assay was intended as an aid for orientation, but cannot be used
for precise measurement of the IC50 value, because it is error-prone. Nevertheless, this
is more informative than residual activities itself.
Harmine and 5-Iodotubercidin were used as control compounds for IC50 determination.
5-Iodotubercidin has a structure similar to adenosine and is used as a general kinase
inhibitor, especially as adenosine kinase inhibitor. This adenosine derivative has been
shown to affect cell proliferation and survival and is suggested to be a potential
chemotherapeutic drug (Zhang et al., 2013). However, 5-Iodotubercidin was previously
reported to be a specific inhibitor of DYRK2 and Haspin, with a high selectivity in a
screening against a panel of 98 kinases (Eswaran and Knapp, 2010). Furthermore, our
Figure 11: Dose response curves of selected compounds.
Dose response curves were ascertained by using the Kinase-GLO assay from PROMEGA. IC50 values for
DYRK1A inhibition were calculated with the help of the GraphPad Prism 5.0 program after automatically
outlier elimination of one experiment for AnnH12, AnnH22, AnnH26_2, AnnH32_2 and two experiments
for harmine, AnnH21, AnnH31. 5-Iodotubercidin was tested five times (data shown as means + SEM).
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group had already reported that 5-Iodotubercidin is a potent inhibitor of DYRK1A
as well (Walte et al., 2013) and so it was used as an additional control substance.
The ascertained dose response curves showed increasing potencies in the following
order: AnnH21 < AnnH22 < AnnH12 < AnnH32_2 < AnnH26_5 < Harmin <
5-Iodotubercidin < AnnH31 and were used as an aid for orientation.
Subsequently, all those new DYRK1A inhibitors were tested for their inhibitory effect
on MAO A that fulfilled the criteria of comparable or better DYRK1A inhibition
in comparison to harmine (cf. table 1). Compounds are clarified to be no inhibitors
of MAO A when the inhibition was less than 5% at a concentration of 1 µM. From
originally 37 only 15 compounds remained and additionally AnnH31 was included in
this selection as a potent DYRK1A inhibitor, although this compound was still a weak
inhibitor of MAO A and showed an average inhibition of 25% at 1 µM (table 2).
Furthermore, these compounds were examined for selectivity against some related
kinases that are known to be targeted by other DYRK1A inhibitors, i.e. DYRK1B,
DYRK2, HIPK2 and CLK1 (Tahtouh et al., 2012). Overall, most compounds
showed a similar profile towards these kinases (table 2). All inhibitors showing high
potency for DYRK1A also inhibited DYRK1B, although slightly less efficiently than
DYRK1A. In contrast, DYRK2 and HIPK2 are only weakly inhibited by these new
β-carbolines. The strongest inhibition of DYRK2 was induced by AnnH75 (42%
remaining kinase activity) and for HIPK2 AnnH69 showed the strongest inhibitory
effect (33% remaining kinase activity). Similar to other known DYRK1A inhibitors,
most compounds were also active against CLK1, except for those with the least
potency for DYRK1A (AnnH28_2 with 99%, AnnH57 with 63% and AnnH76 with
71% remaining CLK1 activity, respectively).
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Table 2: Inhibition of DYRKs, related kinases and MAO A.
Chosen compounds were tested at 1µM on DYRKs, related kinases and MAO A as described in the
experimental procedures. The average of residual kinase activities is given in percentage and the number
of performed experiments is noted in brackets.
compound [1 µM] DYRK1A MAO A DYRK1B DYRK2 HIPK2 CLK1
harmine 27 ± 13 2.5 11 92 79 23
(n=23) (n=11) (n=5) (n=8) (n=3) (n=10)
AnnH12 30 101 24 86 106 45
(n=3) (n=3) (n=3) (n=4) (n=3) (n=5)
AnnH18_5 27 124 50 51 95 58
(n=3) (n=3) (n=3) (n=4) (n=3) (n=4)
AnnH24 10 103 44 63 91 17
(n=3) (n=3) (n=3) (n=)4 (n=3) (n=4)
AnnH28_2 36 131 88 92 100 99
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH31 8 75 7 59 70 11
(n=9) (n=4) (n=3) (n=3) (n=3) (n=7)
AnnH32_2 12 105 51 100 90 44
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH38 12 127 39 93 93 31
(n=3) (n=3) (n=3) (n=4) (n=3) (n=4)
AnnH42 22 115 43 81 96 44
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH43 5 102 14 56 84 10
(n=5) (n=3) (n=3) (n=4) (n=3) (n=4)
AnnH52 36 118 63 76 73 45
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH57 33 97 56 95 96 63
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH67 17 101 59 100 74 34
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH69 17 122 60 61 33 33
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH74 12 112 35 85 97 46
(n=3) (n=3) (n=3) (n=3) (n=3) (n=3)
AnnH75 10 119 32 42 85 24
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
AnnH76 35 112 75 80 98 71
(n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
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The three promising compounds AnnH31, AnnH43 and AnnH75 were further
characterized and therefore the IC50 values for DYRK1A inhibition were determined
using radioactive assays, which are considered as the gold standard for measuring
kinase activities (Hastie et al. 2006). AnnH31, AnnH43 and AnnH75 posses the
scaffold of harmine with substituted nitrile groups at the N-9 (fig. 12). AnnH31 can
Figure 12: Chemical structure of A: AnnH31, B: AnnH43 and C: AnnH75.
AnnH31: (7-Methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)-acetonitril.
AnnH43: (±)-2-(7-Methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)-propannitril.
AnnH75: (1-Chlor-7-methoxy-9H-pyrido[3,4-b]indol-9-yl)acetonitril.
be chemically also named 9-Cyanomethylharmin. AnnH43 is chemically specified a
cyanomethyl combination of AnnH31 with a branching at the methyl group. Following
the chemical nomenclature AnnH75 is a chlorinated analogue of harmine with an N-9
alkylation. The radioactive assay as gold standard for measuring kinase activities
(Hastie et al. 2006) identified AnnH31 as the most potent DYRK1A inhibitor with
an IC50 value of 81 nM, followed by AnnH75 and AnnH43 with IC50 values of 184 nM
and 202 nM, respectively (fig. 13).
Furthermore, these three new β-carboline analogues were further characterized
regarding their effectiveness of MAO A inhibition. The IC50 values were determined
using the MAO-GLO™Assay from Promega. Three independent experiments showed
that AnnH75 had the lowest potency for MAO A inhibition with an IC50 value above
10 µM. AnnH43 and AnnH31 showed also a reduced inhibitory effect on MAO A with
IC50 values of 5.39 µM and 3.24 µM, respectively, in comparison to harmine with an
IC50 value of 0.05 µM (fig. 14).
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Figure 13: IC50 values of DYRK1A inhibition.
Dose response curves were drawn after radioactive activity asays. IC50 values were calculated with the
help of the GraphPad Prism 5.0 program after automatically outlier elimination. The graph presents the
results of three to five independent assays of each inhibitor (data shown as means ± SEM).
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Figure 14: IC50 values of MAO A inhibition.
Dose response curves were drawn after MAO-GLO™asays. IC50 values were calculated with the help of
the GraphPad Prism 5.0 program after automatically outlier elimination. The graph presents the results
of three independent asays of each inhibitor (data shown means as ± SEM).
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Considering the aim to develop a chemical probe for the functional characterization
of DYRK1A in animal experiments, AnnH75 seemed the most promising compound.
Although more potent, AnnH31 is compromised by residual MAO A inhibition, and
we assumed that AnnH75 might exhibit enhanced metabolic stability over AnnH43
due to the chlorination of ring C (cf. fig. 12).
The selectivity of AnnH75 was profiled against a panel of 300 wild-type protein kinases
at a concentration of 1 µM (for a list of all kinases with residual activities see table S2).
This screening identified CLK1, CLK4, Haspin/GSG2, DYRK1A and DYRK1B as
those kinases most potently inhibited by this new β-carboline analogue (fig. 15 A).
Figure 15: Selectivity profile of AnnH75.
AnnH75 was profiled at a concentration of 1 µM against a panel of 300 wild type protein kinases (n=2).
A, The kinome dendrogram was adapted and is reproduced by courtesy of Cell Signaling Technology. Red
spheres highlight those kinases, which are inhibited by AnnH75 by more than 50%. Haspin is also known
as GSG2.
B, Lorenz curve and Gini coefficient were made applying a Microsoft Excel spreadsheet of Graczyk (2007).
The gray line corresponds to a Gini value of zero and consequently would represent a lack of selectivity.
The selectivity score was calculated according to Karaman et al. (2008).
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As parameters for the overall kinase inhibitor selectivity, the Gini coefficient (Grazcyk,
2007) as well as the selectivity score (Karaman et al., 2008) were calculated (fig.
15 B). The Gini coefficient reflects the degree to which the inhibitory activity of
a compound (calculated as the sum of inhibited kinases) is directed towards only
a single kinase or is distributed equally across all tested kinases. A Gini value of
one corresponds to an absolutely selective inhibitor and a Gini value of zero to a
nonselective compound. The Gini coefficient and thereby the relative selectivity of an
inhibitor does not depend on the ATP concentration, but doubtless on the inhibitor
concentration. The Lorenz curve functions as visualization of these datasets. According
to these metrics, the new β-carboline AnnH75 possesses a Gini score of 0.625 and a
selectivity score of 0.04. Both parameters are in line with recently published results
on harmine (Cozza et al., 2013)(table 3).
Table 3: Crossreactivity of AnnH75 and harmine.
The table shows the residual activities [in %] of the most important kinases targeted by AnnH75 in
comparison to harmine from different literature. Additionally, all Gini values are indicated. Haspin is also
known as GSG2. - indicates not determined residual activities of the perspective kinase. Residual activities
of 10% or lower are highlighted in grey.
Cozza Bain Tahtouh
et al., 2013 et al., 2007 et al., 2012
AnnH75 Harmine Harmine Harmine
[1 µM] [1 µM] [1 µM] [10 µM]
CLK1 0 - - 0.35
CLK2 43 10 - 2.6
CLK3 74 - - 42
CLK4 -1 - - 2.1
DYRK1A 8 2 4 0.1
DYRK1B 8 - - 2
DYRK2 68 35 15 61
DYRK3 57 31 6 -
DYRK4 94 - - -
haspin 5 - - -
HIPK1 91 119 - 14
HIPK2 87 68 108 34
HIPK3 88 118 87 44
HIPK4 88 - - 90
IRAK1 95 - - 66
Gini 0.625 0.627 0.485 0.843
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The pattern of crossreactivity obtained by the selectivity profile of AnnH75 is also
typical for other, chemically unrelated DYRK1A inhibitors, such as leucettine L41,
leucettamine B, INDY and the substituted thiophene compounds 48 and 29 (table 4).
This pattern is likely to reflect the similar geometry of the ATP-binding pocket in
these kinases. The leucettamine B analogue L41 is more potent regarding DYRK1A
inhibition than the lead structure leucettamine B, but the modifications also resulted
in a lower selectivity. Leucettamine B has a Gini value of 0.862 at a concentration of
10 µM and its analogue leucettine L41 reaches a Gini value of only 0.673 at the same
concentration (calculated from the supplemental data of Tahtouh et al., 2012).
Table 4: Crossreactivity of DYRK inhibitors.
The table shows the residual activities [in %] of the most important kinases targeted by AnnH75 in
comparison to other inhibitors from literature. Additionally, all calculated Gini values are indicated. Haspin
is also known as GSG2. - indicates not determined residual activities of the perspective kinase. Residual
activities of 10% or lower are highlighted in grey.
Tahtouh Tahtouh Ogawa Cuny Schmitt Schmitt
et al., 2012 et al., 2012 et al., 2010 et al., 2012 et al., 2014 et al., 2014
AnnH75 L41 Leucet. B INDY 42 48 29
[1 µM] [10 µM] [10 µM] [10 µM] [10 µM] [5 µM] [5 µM]
CLK1 0 0.25 2.2 1 0 6 4
CLK2 43 5.6 10 12 1 22 28
CLK3 74 2 73 30 63 69 88
CLK4 -1 0 2.6 0 - 1 -5
DYRK1A 8 0.2 1.6 IC50=0.24µM 0 3 10
DYRK1B 8 4 11 IC50=0.23µM 2 0 0
DYRK2 68 0.6 57 3 14 0 7
DYRK3 57 - - 0 3 31 34
DYRK4 94 - - 13 - 88 87
haspin 5 - - - -1 - -
HIPK1 91 0.75 34 64 59 91 96
HIPK2 87 11 60 - 47 - -
HIPK3 88 3.8 45 - 51 - -
HIPK4 88 44 91 - 72 93 7
IRAK1 95 2.8 100 - 47 - -
Gini 0.625 0.673 0.862 0.342 0.652 0.724 0.741
Even in comparison to harmine, with a Gini coefficient of 0.843 at 10 µM (calculated
from the supplemental data of Tahtouh et al., 2012, cf. table 3), L41 is less selective. In
particular, leucettine L41 and leucettamine B inhibit members of the CLK family more
potently than AnnH75. Furthermore, in contrast to L41 the β-carbolines harmine,
AnnH75 and compound 42 have a much lower inhibitory activity against DYRK2 and
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HIPK1-4. Strong inhibition of IRAK1 seems to be a side effect of leucettine L41 and
strong inhibition of HIPK4 seems to be a side effect of the thiophene compound 29,
which may not pertain to all DYRK inhibitors (table 4).
3.1.1.1 Desaza-harmines as special group of β-carboline analogues
One special group of newly synthesized β-carboline analogues are the desaza-harmines.
They stand out due to the substitution of the nitrogen by a carbon on position 9
respectively position 2 on the scaffold of harmine (fig. 16). These special compounds
were synthesized to prove if both nitrogens of harmine are essential for its inhibitory
effects on DYRK1A and MAO A.
Figure 16: Structural comparison of desaza-harmines.
Positions on which a nitrogen was substituted by a carbon atom are marked by a red circle. Harmine is
depicted as lead structure.
According to Reniers and co-workers (2011) the interaction of harmine and MAO A
is mainly established via the functional NH-group of the middle pyrrole ring. That
means that a substitution of the functional nitrile group on position 9 should lead to
a decreased inhibition of MAO A, which was desired in this study. Additionally, it is
known that the replacement of the methyl moiety on position 7 of harmine by lipophilic
groups like a cyclohexyl, a phenyl and an aliphatic chain increases the inhibition of
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MAO A compared to harmine (Reniers et al., 2011). These lipophilic groups are able
to interact with a lipophilic pocket and to stabilize the binding to MAO A. This
pocket is unoccupied by harmine and consequently the methyl moiety on position
7 of harmine should not be altered for a decrease of MAO A inhibition. According
to our collaborator Wolfgang Sippl also the interaction of harmine and DYRK1A is
caused by the middle pyrrole ring on position 9 (cf. fig. 7) (Becker and Sippl, 2011). A
substitution of this functional group should lead to a decreased inhibition of DYRK1A
as well.
Table 5 shows the residual activities of DYRK1A, DYRK2, CLK1 and MAO A
after treatment with 1 µM of the respective desaza-harmine in Kinase-GLO assay
or MAO-GLO assay, respectively. All desaza-harmines showed the expected decreased
inhibitory effect on DYRK1A with the exception of AnnHT5, which inhibits DYRK1A
in the same way as harmine, but without inhibitory effects on MAO A. Especially the
2-desaza-harmine AnnHOG3 confirmed the idea of decreased DYRK1A and MAO A
inhibition, because the replacement of the functional NH-group of the pyridine ring
led only to minimal inhibitory effects on all tested kinases.
Table 5: Inhibition of DYRK1A, DYRK2, CLK1 and MAO A by desaza-harmines.
Desaza-harmines were tested at 1µM on DYRK1A, DYRK2, CLK1 and MAO A as described in the
experimental procedures. The average of residual kinase activities are shown as percentage and the number
of performed experiments is noted in brackets.
compound [1 µM] DYRK1A DYRK2 CLK1 MAO A
harmine 27 ± 13 92 23 2.5
(n=23) (n=8) (n=10) (n=11)
AnnHOG3 72 91 96 90
(n=3) (n=1) (n=3) (n=3)
AnnHT2 47 86 54 12
(n=3) (n=1) (n=3) (n=4)
AnnHT3 60 99 75 36
(n=3) (n=1) (n=3) (n=6)
AnnHT5 28 81 7 100
(n=3) (n=1) (n=3) (n=3)
AnnHT6 46 91 27 44
(n=3) (n=1) (n=3) (n=4)
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3.1.2 Inhibition of DYRK1A activity in cell culture
Next, some new harmine analogues were evaluated for their capacity of inhibiting
DYRK1A in cells. Therefore, the effect of AnnH75 was compared to some other
compounds developed for DYRK1A-catalysed phosphorylation of the splicing factor
SF3b1, which is known to be phosphorylated by DYRK1A on threonine on
position 434 (de Graaf et al. 2006). HeLa cells were transiently transfected with an
expression vector for a fusion protein of GFP and the N-terminus (amino acids 1-492)
of SF3b1 and then treated with 1 µM of the respective compound (fig. 17 A). The most
potent compounds were AnnH24, AnnH31, AnnH38, AnnH44, AnnH63 and AnnH75,
which inhibited the substrate phosphorylation activity of DYRK1A at least by 70%
(fig. 17 B).
Figure 17: Inhibition of SF3b1 phosphorylation on threonine 434 by chosen compounds.
A, HeLa cells were transfected with pEGFP-SF3b1-NT and treated with 1 µM of the indicated compound
for 18 h. Immunoblotting with pT434 antibody determined the phosphorylation state of SF3b1, and the
results were normalized to the total amount of SF3b1 immunoreactivity (GFP). The vertical line shows
where two blots were stitched.
B, The column diagram shows the quantitative evaluation of three independent experiments for each
compound (data shown as mean + SD, * = p < 0,05, ** = p < 0,005 in the Dunnett’s multiple
comparison test against the control harmine).
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Some compounds were chosen to be further investigated and transfected HeLa cells
were treated with three concentrations of the respective inhibitor. Western blot
analysis showed a concentration-dependent reduction of phospho-threonine 434 levels
by all chosen compounds, but with different potencies (fig. 18). AnnH79 was used
as a β-carboline compound with slight potency on DYRK1A inhibition and MAO A
inhibition. Except for AnnH73, all other tested compounds exhibited potencies similar
to harmine and reduced the phosphorylation of SF3b1 at threonine 434 by ∼90%,
when applied at a concentration of 1 µM.
Figure 18: Inhibition of SF3b1 phosphorylation on threonine 434 in HeLa cells.
HeLa cells were transfected with pEGFP-SF3b1-NT and treated with the indicated compound
concentration for 18 h. Immunoblotting with pT434 antibody determined the phosphorylation state of
SF3b1, and the results were normalized to the total amount of SF3b1 immunoreactivity. The column
diagram shows the quantitative evaluation of three to four independent experiments for each compound
(data shown as mean + SD). AnnH79 was used as negative control in one experiment. Statistical analysis
revealed any significant differences in comparison to control harmine at any concentration.
The same experiment was repeated for comparison of AnnH75 to the known
DYRK1A inhibitors INDY and L41. Transfected HeLa cells were treated with three
concentrations of the respective inhibitors and Western blot analysis revealed a
concentration-dependent reduction of phospho-threonine 434 levels by all inhibitors.
INDY showed the lowest inhibition, while L41 had the most potent inhibitory effect on
DYRK1A even at concentrations of 0.33 µM (fig. 19). The new β-carboline AnnH75
showed an inhibition comparable to the control harmine.
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Figure 19: Comparison of the inhibitiory potency of AnnH75, INDY and L41 on SF3B1
phosphorylation.
A, HeLa cells were transfected with pEGFP-SF3b1-NT and treated with the indicated compound
concentration for 18 h. Immunoblotting with an pT434 antibody determined the phosphorylation state
of SF3b1, and the results were normalized to the total amount of SF3b1 immunoreactivity.
B, Column diagrams show quantitative evaluation of four independent experiments for each compound
(data shown as mean + SD). Statistical analysis revealed any significant differences in comparison to
control harmine at any concentration.
In order to determine IC50 values for the two most potent new DYRK1A inhibitors
in a different independent cell-based assay, the phosphorylation of the DYRK1A
substrate septin 4 (SEPT4) was measured. In 2008, Sitz and co-workers showed
that the phosphorylation of SEPT4 results in a reduced electrophoretic mobility
of SEPT4, which can be detected and quantified by Western blot analysis. HeLa
cells were transiently transfected with an expression vector for FLAG-tagged
SEPT4 and then treated with AnnH31 and AnnH75. This treatment resulted in a
concentration-dependent decrease of the intensity of the slower migrating band and
an associated increased signal of the lower band (fig. 20B). Quantitative evaluation
of three independent experiments revealed IC50 values of 49 nM and 363 nM for
AnnH31 and AnnH75, respectively (fig. 20A). These values are close to the potencies
determined in the radioactive in vitro assay (cf. fig. 13), indicating that both new
β-carboline compounds are cell permeable inhibitors of DYRK1A.
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Figure 20: Inhibition of SEPT4 phosphorylation in HeLa cells.
HeLa cells were transfected with FLAG-Septin4, incubated for 48 h and treated for 5 h with the indicated
compound concentration. Immunoblotting with a FLAG-tag antibody determined the amount of Septin4
and the ratio of immunoreactivity of upper to lower band was defined to assess the IC50 values.
A, The curve diagram shows a quantitative evaluation of three independent experiments for each
concentration (data shown as mean ± SD) resulting in IC50 values of 363 nM for AnnH75 and 49 nM
for AnnH31.
B, Representative Western blot including 1 µM 5-Iodotubercidin (Iodo) as positive control.
3.1.2.1 Cytotoxicity
Subsequently, the effect of AnnH31, AnnH75 and some other harmine analogues
on the viability of cells was analyzed. Therefore, three different clonal cell
lines were used (HeLa, PC12 and SH-SY5Y) and the Cell Proliferation
Assay XTT from AppliChem was performed. This system works with
2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT),
which only mitochondria of living cells are able to reduce into colored formazan
compounds. Concentrations of the XTT formazan are proportional to the number of
metabolically active cells. All cells were treated with three different concentrations
of the respective compound for three days, except for staurosporine, which was used
as control just at 1 µM. This wide-range kinase inhibitor showed high cytotoxicity
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in all three investigated cell lines. The treatment with AnnH75 caused only minimal
cytotoxic effects in HeLa and PC12 cells up to concentrations of 10 µM. However,
treatment with high concentrations of AnnH24, AnnH31 and AnnH43 reduced
cell viability (table 6). The cytotoxic effects of harmine were already investigated
by Göckler and co-workers in 2009 and they had reported that harmine showed
cytotoxicity at concentrations higher than 3 µM in HeLa and HEK293 cells. In
general, the SH-SY5Y neuroblastoma cell line was more sensitive towards all tested
compounds than the other two cell lines.
Table 6: Cytotoxicity of new β-carboline inhibitors.
The table shows the cell viability [in %] of tested cell lines treated with the compounds indicated.
5-Iodotubercidin and staurosporine were used as control. The lowest cell viability for each concentration
is highlighted in grey (n=4).
HeLa PC12 SH-SY5Y
1 µM 3 µM 10 µM 1 µM 3 µM 10 µM 1 µM 3 µM 10 µM
AnnH24 97 96 72 95 90 81 75 66 45
AnnH31 93 80 55 89 88 70 81 88 38
AnnH43 91 80 66 88 88 90 61 68 45
AnnH44 84 80 58 85 87 78 64 75 42
AnnH63 92 90 52 95 77 47 80 72 59
AnnH73 92 85 60 99 94 90 100 56 55
AnnH75 100 93 92 94 100 95 89 73 43
5-Iodotubercidin 67 16 18 62 17 5 13 10 15
Staurosporine 8 18 6
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3.1.3 AnnH75 inhibits tyrosine autophosphorylation of DYRK1A in vitro
DYRKs have been postulated to exhibit differential inhibitor sensitivities of
their tyrosine autophosphorylation activity and their serine/threonine substrate
phosphorylation activity (Lochhead et al. 2005). This difference was examined
for Drosophila dDYRK2 and has to be still specified for DYRK1A. Therefore,
it was investigated if the new β-carboline AnnH75 is a specific inhibitor of the
serine/threonine kinase activity of mature DYRK1A or whether AnnH75 is also
capable of inhibiting tyrosine autophosphorylation taking place during translation.
To address this question, a coupled in vitro-transcription-translation system was
used, which allowed to monitor the effect of the inhibitor on the tyrosine
autophosphorylation of DYRK1A and the phosphorylation of threonine 434 in the
substrate protein SF3b1 at the same time (fig. 21). Therefor pET-ST2-DYRK1A WT
and SF3b1-NT-His6 were co-expressed in the in vitro translation system PURExpress
in presence of different AnnH75 concentrations, followed by Western blot analysis for
determining the different phosphorylation levels. Under the chosen conditions, tyrosine
autophosphorylation of DYRK1A was reduced at concentrations higher than 1 µM of
AnnH75, while slightly higher concentrations were required for inhibition of substrate
phosphorylation (fig. 21 A, B). The IC50 value for inhibition of autophosphorylation
was calculated at 1.88 µM and for substrate phosphorylation at 5.72 µM. The much
higher IC50 value for substrate phosphorylation in comparison to the peptide assay
(IC50=184 nM, fig. 13) is due to the fact that the phosphorylation of recombinant
SF3b1 in the in vitro translation mix does not occur under conditions of substrate
saturation (Walte et al., 2013) (fig. 21 A), but shortening the in vitro translation to
half an hour accelerated the substrate phosphorylation (fig. 21 C).
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Figure 21: AnnH75 inhibits SF3b1 phosphorylation by DYRK1A and DYRK1A
autophosphorylation in vitro.
In vitro translation of pETST2-DYRK1AWT and SF3b1-NT-His6 in presence of AnnH75. Phosphorylation
of tyrosines in DYRK1A and threonine 434 in SF3b1 was determined by immunoblotting with pY99
or pT434 antibodies, and the results were normalized to the total amount of DYRK1A or SF3b1
respectively. A, Quantitative evaluation of three independent experiments after 1 h of translation. Means
are plotted as normalized phospho-immunoreactivity relative to untreated cells ± SEM. Representative
Western blots are shown after 60 min (B) and 30 min (C) of translation. ∼ unidentified bands.
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3.2 Characterization of dual specificity kinase activity of
DYRK1A
3.2.1 Tyrosine autophosphorylation of CMGC kinases
In order to investigate the mechanism of dual specificity kinase activity in mammalian
DYRK1A, several kinases of the CMGC group with known phosphotyrosine sites in the
activation loop were selected to assess their capacity for tyrosine autophosphorylation.
The kinases were expressed in Escherichia coli as single domain proteins fused to an
N-terminal Strep-tag (lacking the non-catalytic regions). CLK1 was also included as
a related kinase although it lacks the conserved tyrosine residue in the activation loop
(for a sequence alignment of the activation loop see Table S3). Furthermore, additional
constructs for DYRK2 and DYRK4 were generated to assess the requirement of the
NAPA region for tyrosine autophosphorylation (Kinstrie et al., 2010). After the single
domain proteins were expressed in E. coli, phospho-tyrosine levels were detected by
immunoblot analysis (fig. 22 A). As expected, the kinase deficient mutant K188R of
DYRK1A showed no detectable phospho-tyrosine signal, but the wild type DYRK1A
as well as both DYRK2 constructs and HIPK2 showed high tyrosine phosphorylation
levels. The expression of DYRK1B and DYRK4 constructs seemed to be incomplete,
which may be caused by suboptimal conditions for these expression constructs.
Unexpectedly, in this expression system the tyrosine autophosphorylation of human
DYRK2 did not depend on the NAPA region (fig. 22 A,B). Immunoblot analysis
was repeated with two other phospho-tyrosine specific monoclonal antibodies (PY20,
PY100) in order to increase tyrosine phosphorylation signals, but both additional
antibodies lead to the same result (data not shown).
Next, the tyrosine autophosphorylation was examined in an E. coli-based coupled
in vitro transcription–translation system to check if other expression conditions
would lead to a better expression or tyrosine phosphorylation of some constructs.
The PURExpress system is reconstituted from recombinant proteins and purified
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ribosomes, which excludes effects of unknown proteins such as chaperones and this
system is better verifiable as the expression in E. coli. Likewise, wild type DYRK1A,
HIPK2, CLK1 and slightly DYRK2 were autophosphorylated on tyrosine residues
when expressed in vitro, indicating that the tyrosine kinase activity of these kinases
is an intrinsic property of the catalytic domain and does not require co-factors
(fig. 22 B). All attempts to produce tyrosine phosphorylated DYRK1B, DYRK3,
DYRK4, CDKL5 or PRP4 constructs by in vitro translation failed.
Figure 22: Tyrosine autophosphorylation of selected CMGC kinases.
A, Expression constructs comprising the catalytic domains of the indicated kinases fused to an N-terminal
Strep-tag were expressed in E. coli for 3 h at 37°C. Tyrosine phosphorylation was assessed by
immunoblotting of total cell lysates with a phospho-tyrosine (pTyr) specific antibody (PY99). Total
protein was detected using a Strep-Tactin-peroxidase conjugate. NAPA indicates constructs that include
the NAPA region and K188R (KR) is a point mutant of DYRK1A defective in ATP binding. Representative
western blot of two independent experiments.
B, Expression in a cell free E. coli-derived expression system. Coupled in vitro transcription and translation
reactions were incubated for 2 h at 37°C. The asterisk (*) marks an unidentified band. A representative
western blot of three independent experiments is shown.
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3.2.1.1 DYRK1A tyrosine autophosphorylation is not limited to Y321 in
the activation loop
Another intention was to find out whether DYRK1A can also autophosphorylate on
tyrosines other than those in the activation loop (Y321). Moreover this issue was also
analyzed for DYRK2, a member of class II DYRKs. Therefor different point mutants
were expressed in E. coli. The kinase deficient point mutants DYRK1A K188R
and DYRK2 D378N were used as control. As expected, these two mutants showed
no detectable phospho-tyrosine signals. Interestingly, DYRK1A Y321F showed no
altered level of tyrosine phosphorylation in comparison to wild type DYRK1A,
whereas for DYRK2 Y348F no phospho-tyrosine signal was detectable (fig. 23 A).
Additionally, a mutation of another tyrosine in DYRK1A (Y145) was investigated,
which has been found to be phosphorylated in phosphoproteomic studies (Rush et al.,
2005) (PHOSPHOSITEPLUS, www.phosphosite.org). But also this point mutation
did not reduce the immunodetectable phospho-tyrosine level. Furthermore, DYRK1A
point mutants were expressed in the in vitro translation system PURExpress, which
confirmed the result of bacterial expression (fig. 23 B).
Figure 23: DYRK1A autophosphorylates on tyrosines apart from Y321.
Tyrosine phosphorylation of wild type DYRK1A or DYRK2 and the indicated point mutants was analyzed
after overnight expression in E. coli at room temperature (A) or in the PURExpress system for 2h
at 37°C (B). In vitro-expressed DYRK1A migrates as a doublet, of which the upper band (#) is
autophosphorylated. The asterisk (*) marks an unidentified band. A representative western blots of three
independent experiments is shown.
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3.2.2 Posttranslational tyrosine autophosphorylation of DYRK1A
Next, the earliest time point for phospho-tyrosine detection was determined. Hence,
the in vitro translation of DYRK1A was stopped at different time points and the
phospho-tyrosine levels were monitored. This time-course experiment showed that
tyrosine phosphorylation was already detectable after 30 min to 60 min, clearly before
the Strep-tag signal appears after ∼ 2 h of translation (fig. 24). This result indicates
that tyrosine autophosphorylation of DYRK1A is a very early event.
Figure 24: Earliest time point for phospho-tyrosine detection of DYRK1A.
In vitro translation of wild type DYRK1A (WT) and DYRK1A-K188R was stopped at different time points
as indicated. Levels of phospho-tyrosine was analyzed by Western blotting. The vertical line indicates where
irrelevant lanes were deleted from the final image.
For investigation of the posttranslational tyrosine autophosphorylation the fusion
protein SBP-DYRK1Acat was used. In this construct the catalytic domain of
DYRK1A was fused N-terminally to a streptavidin binding peptide (SBP) tag,
which has a high affinity for streptavidin. The mild elution conditions allow the
purification of native proteins by using biotin. SBP-DYRK1Acat was expressed in the
in vitro translation system PURExpress in absence or presence of 5-Iodotubercidin or
staurosporine and stopped after 2 h by adding EDTA and RNAse A on ice, to degrade
existing mRNA. SBP-DYRK1Acat was purified by DynaBeads M-280 to eliminate
the inhibitor, eluted in biotinylated elution buffer and continued to be incubated with
1 mM ATP at 37°C for different time periods.
Directly after translation in the presence of the inhibitor 5-Iodotubercidin, mature
DYRK1A was not phosphorylated on tyrosine residues (fig. 25 A). The following
incubation with ATP did not influence the phospho-tyrosine level of non-inhibited
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DYRK1A, but enabled the inhibited, initially not phosphorylated kinase to
phosphorylate itself posttranslationally on tyrosine residues (fig. 25 B). Withal,
this posttranslational phosphorylation event took place very rapidly within 1 h.
Additionally, after elution the activity of inhibited DYRK1A was tested in the
ADP-GLO assay from PROMEGA (fig. 25 C). Residual activities of DYRK1A after
inhibition with both non selective inhibitors revealed that DYRK1A was inhibited at
least by 45%, but was still able to phosphorylate posttranslationally on tyrosines.
Figure 25: Posttranslational DYRK1A phosphorylation.
A, In vitro translation of wild type SBP-DYRK1Acat was stopped after 2 h in absence or presence of
5-Iodotubercidin.
B, Add-on incubation with 1 mM ATP at 37°C after purification and elution with DynaBeads M-280.
C, Residual activities of six independent experiments were calculated after ADP-GLO assay with eluted
SBP-DYRK1Acat wild type. Control samples (-) not pretreated with inhibitor are set as 100% DYRK1A
activity.
Likewise, the DYRK1A point mutant Y321F was investigated regarding its ability
to phosphorylate posttranslationally on tyrosine residues after in vitro translation in
presence of 5-Iodotubercidin. SBP-DYRK1Acat wild type and the SBP-DYRK1Acat
Y321F point mutant were compared and it was shown that DYRK1A Y321F is
also able to phosphorylate itself posttranslationally on tyrosine residues (fig. 26 A).
This indicates that the subsequent phosphorylation of DYRK1A does not occur
solely on tyrosine on position 321. After inhibition with staurosporine also DYRK1A
Y321F was tested for its residual activity in the ADP-GLO assay (fig. 26 B). Three
independent experiments revealed that DYRK1A Y321F was inhibited at least by
54% and therefore the reduced activity after inhibition seems not to depend on the
phosphorylation state of the tyrosine in the activation loop.
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Figure 26: Posttranslational DYRK1A wild type and Y321F phosphorylation.
A, In vitro translation of SBP-DYRK1Acat WT and SBP-DYRK1Acat Y321F was stopped after 2 h in
presence of 5-Iodotubercidin and after purification and elution with DynaBeads M-280 the kinase was
additionally incubated with 1 mM ATP at 37°C. The vertical line indicates where irrelevant lanes were
deleted from the final image.
B, Residual activities of three independent experiments were calculated after ADP-GLO assay with eluted
SBP-DYRK1Acat Y321F.
Following the same principle, pET-ST2-DYRK1A was translated in vitro in absence or
presence of staurosporine to produce a hypo-phosphorylated protein. For this purpose,
the expression of DYRK1A was run with or without staurosporine and stopped after
2 h by adding RNAse A and kanamycin, as an inhibitor of bacterial translation.
Then all samples were diluted 100-fold to ensure a staurosporine concentration
without inhibitory effects on DYRK1A. Subsequently, samples were incubated with
500 µM ATP at 37°C (fig. 27). Staurosporine did not affect the in vitro translation
of DYRK1A and the uninhibited kinase showed no alterations in phosphorylated
tyrosine levels independent from the additional ATP incubation time. In contrast,
hypo-phosphorylated DYRK1A was able to phosphorylate, even though the maximal
tyrosine phosphorylation intensity was not achieved (fig. 27 A). Densitometrical
evaluations showed a significant increase of tyrosine phosphorylation already after
2 h of additional incubation (fig. 27 B). This experiment shows that tyrosine
autophosphorylation of DYRK1A is also possible after termination of translation. This
approach takes advantage of the fact that tyrosine autophosphorylation of DYRKs is
an intramolecular reaction (Lochhead, 2009) and thus independent from the enzyme
concentration. It must be noted that the phosphotyrosine-specific antibody does not
discriminate between the phosphorylation of Y321 in the activation loop and other
tyrosines (see fig. 23).
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Figure 27: Posttranslational tyrosine autophosphorylation of DYRK1A.
In vitro translation of DYRK1A with or without 30 µM staurosporine was stopped after 2 h by adding
kanamycin and RNAse. Reactions were diluted 100-fold and further incubated with ATP (500 µM) at
37°C. Phospho-tyrosine was detected by Western blot analysis (A) and relative tyrosine phosphorylation
was evaluated densitometrically as ratio of phospho-tyrosine signal to whole protein amount (B). Data
are shown as means + SD of three independent experiments. The one-sample t test was applied to test
significance of treatment effects with the help of the GRAPHPAD PRISM 5.0 program. Effects were
considered statistically significant at p < 0.05.
3.2.3 Differential effects of kinase inhibitors on autophosphorylation and
substrate phosphorylation
The current model for the mechanism of tyrosine autophosphorylation in DYRK
family members is based on a study of the Drosophila DYRKs dDYRK2 and
MNB (Lochhead et al., 2005). This model implies that the autophosphorylation
on tyrosine residues appears only in a translational folding intermediate of DYRKs
with biochemical properties different from the mature kinase. Especially the kinase
inhibitor sensitivities of tyrosine autophosphorylation and substrate phosphorylation
of Drosophila dDYRK2 were shown to differ from each other.
Following this approach, the different conformational states of DYRK1A that may
account for its dual specificity kinase activity were analyzed pharmacologically. As a
model for the translational folding intermediate form of DYRK1A, the point mutation
of tyrosine 321 to phenylalanine was used. First, harmine as well known potent
DYRK1A inhibitor was studied in respect to its inhibitory potency on the Y321F
mutant. Therefor HeLa cells were transiently transfected with GFP-tagged constructs
of DYRK1A wild type and Y321F point mutant. Kinases were purified by GFP-Trap
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magnetic beads and then incubated with ATP and different harmine concentrations
(fig. 28). Western blot analysis showed a concentration dependent inhibition of
tyrosine autophosphorylation for wild type, mature DYRK1A and the point mutated,
translational intermediate form of DYRK1A. In both cases the inhibitory effect of
harmine was present already at concentrations of 0.3 µM and consequently the kinase
inhibitor sensitivities of tyrosine autophosphorylation of mature DYRK1A and the
translational intermediate form of DYRK1A did not differ.
Figure 28: Harmine inhibits DYRK1A-Y321F point mutant.
HeLa cells are transiently transfected with GFP-DYRK1A wild type (D1A-WT) and the Y321F mutant
(D1A-Y321F). DYRK1A was purified by GFP-Trap magnetic beads and incubated with different harmine
concentrations for 1 h at 37°C. A representative western blot of two independent experiments is shown.
Next the translational autophosphorylation of tyrosine residues and the subsequent
substrate phosphorylation was investigated. For a broad range of different chemical
scaffolds, a series of various inhibitors was assembled. Harmine, TG003, KH-CB19 and
TBB were used as known DYRK1A inhibitors and compared to the unspecific kinase
inhibitors staurosporine and curcumin. Additionally, 5-Iodotubercidin was included as
a compound reported to inhibit DYRK2 (Eswaran and Knapp, 2010) and also NIH54,
a newly developed derivative of KH-CB19 (Walte et al., 2013). Structures of applied
inhibitors are provided in the supplement (fig. S4). TBB was analyzed, because this
compound had been used to establish the differential inhibitor sensitivity of the
translational intermediate and mature form of dDYRK2 (Lochhead et al., 2005).
Wild type DYRK1A and the point mutant DYRK1A Y321F were translated in vitro
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Figure 29: Effects of kinase inhibitors on tyrosine autophosphorylation and substrate
phosphorylation of DYRK1A.
DYRK1A-WT (A) and DYRK1A-Y321F (B) were in vitro translated in the PURExpress system for 2 h in
the presence of kinase inhibitors as indicated. The top panels show representative Western blots for each
construct. The vertical line indicates where irrelevant lanes were deleted from the final image. For substrate
phosphorylation assays, in vitro expressed DYRK1A or DYRK1A-Y321F was incubated for 5 min with
recombinant SF3b1 and phosphorylation of threonine 434 was detected by Western blot analysis using a
phosphospecific antibody. The column diagrams show the quantitative evaluation of three independent
experiments (data shown as means + SD, *** = p < 0,001 in the Dunnett’s multiple comparison test
against the control harmine).
in presence of the respective inhibitor concentration, followed by incubation with the
DYRK1A substrate SF3b1 for 5 min at 37°C. Western blot analysis revealed that
only three inibitors reduced the tyrosine autophosphorylation of wild type DYRK1A
by more than 50 % (5-Iodotubercidin, harmine and staurosporine) (fig. 29 A, upper
panels). All tested inhibitors reduced the threonine substrate phosphorylation of
DYRK1A wild type by more than 30 %, except of 30 µM TBB (fig. 29 A, lower panel).
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The differential inhibition by 30 µM TBB of DYRK1A Y321F and wild type
DYRK1A was repeated with full length GST-DYRK1A fusion proteins isolated from
E. coli. Hece, this proteins were applied in the kinase-GLO assay with different
TBB concentrations. In contrast to the in vitro approach, the analysis of four
independent experiments showed no differences of substrate phosphorylation for wild
type DYRK1A and DYRK1A Y321F (fig. 30). Consequently, the differential inhibition
of TBB remains an unexplained peculiarity of the in vitro expression system.
Figure 30: TBB dose response curve for DYRK1A wild type and Y321F point mutant.
Kinase-GLO assay was performed with full length constructs of GST-DYRK1A wild type and point mutant
Y321F in presence of different TBB concentrations. IC50 values were calculated fom 4 independent
experiments with the help of the GraphPad Prism 5.0 program (data shown as means ±SD)
.
3.2.4 Inhibitor sensitivity of tyrosine versus threonine
autophosphorylation
One reason for the higher resistance of the tyrosine autophosphorylation assay against
pharmacological inhibition could be that one single phosphorylation event suffices for
maximal signal intensity in 2 h, whereas the substrate phosphorylation assay had been
optimized to a maximal substrate turnover. To ensure the same reaction conditions on
tyrosine and threonine phosphorylation, the sequence segment of SF3b1 comprising
threonine 434 was fused to the C-terminus of SBP-DYRK1Acat in a vector suitable
for bacterial in vitro translation (fig. 31 A) and expressed in the presence of different
inhibitors (fig. 31 B).
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Figure 31: Autophosphorylation on tyrosine and threonine.
A, Schematic representation of the SBP-DYRK1Acat-SF3b1 expression construct. Tyrosines previously
identified to be phosphorylated in proteomic mass spectrometry studies are indicated as Y. Phosphorylated
tyrosine on position 321 in the activation loop of DYRK1A and phosphorylated threonine on position 434
within the fused segment of SF3b1 are highlighted with P. The catalytic domain (cat) is preceded by the
DYRK homology box (shaded).
B, The fusion protein SBP-DYRK1Acat-SF3b1 was in vitro translated for 2 h in the presence of the
indicated inhibitors and wild type SBP-DYRK1Acat (WT) was used as control. The vertical lines indicate
where irrelevant lanes were deleted from the final image. A representative western blot of three independent
experiments is shown..
C, SBP-DYRK1Acat-SF3b1 was in vitro expressed with different concentrations of 5-Iodotubercidin
(Iodo). A representative western blot of three independent experiments is shown.
Western blot analysis revealed a higher sensitivity towards tyrosine
autophosphorylation than towards threonine autophosphorylation, in contrast
to the assay shown in fig. 29 A. Further investigations on this phenomenon with
different concentrations of 5-Iodotubercidin confirmed the higher sensitivity towards
tyrosine autophosphorylation (fig. 31 C). Thus, the differential inhibition of tyrosine
versus threonine phosphorylation in fig. 29 is a consequence of the different reaction
conditions (turnover rate and enzyme/substrate ratio) in these assays. Furthermore,
only the upper bands (fig. 31 # in B, C) contain phospho-tyrosine signals, suggesting
that the faster migrating band represents an inactive form of the fusion protein.
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3.2.5 Characterization of double migrating bands of in vitro expressed
DYRK1A
After Strep-tag detection, in vitro translated DYRK1A always migrated as a double
band in Western blots (cf. fig. 21, fig. 23 B, fig. 27 A, fig. 29, fig. 31). The upper
band was absent in the catalytically inactive DYRK1A mutant K188R, but it could
be observed in the point mutant Y321F (cf. fig. 23 B). Additionally, treatment with
different inhibitors also led to the disappearance of the upper band (cf. fig. 21, fig.
27 A, fig. 29, fig. 31). This could indicate that the mobility shift is due to other
autophosphorylated sites besides the tyrosine in the activation loop and that the
upper band could represent a highly phosphorylated and active form of DYRK1A.
To confirm this idea, pET-ST2-DYRK1A constructs were expressed in the in vitro
translation system PURExpress and then incubated with calf intestinal phosphatase
(CIP) to dephosphorylate all serine, threonine and tyrosine residues. If this hypothesis
was true, the dephosphorylated DYRK1A constructs would migrate faster and just
one band would be detectable by Strep-tag antibody detection. Western blot analysis
Figure 32: CIP treatment of DYRK1A constructs.
pET-ST2-DYRK1A constructs of wild type DYRK1A (WT), Y321F point mutant and kinase deficient
mutant (K188R) were expressed in vitro and treated with calf intestinal phosphatase (CIP) for 1h.
* unspecific band, # slower migrating band of DYRK1A. A representative western blot of two independent
experiments is shown.
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showed that CIP treatment indeed led to unphosphorylated tyrosine residues in
DYRK1A wild type and Y321F point mutant, but the upper, slower migrating band
did not disappear after Strep-tag detection (fig. 32). This indicates that the slower
migrating band cannot only be a high phosphorylated active form of DYRK1A,
because in this case it would disappear after CIP treatment. However, it seems
that the used phospho-tyrosine antibody only detects the slower migrating upper
band, which still could be a hint that the mobility shift is contributed to other
activating posttranslational modifications besides from autophosphorylation or to a
conformational change.
3.3 Verification of the phosphorylation on serine 748
Besides the autophosphorylation of tyrosine residues, DYRK1A is also able to
autophosphorylate on the serine residue on position 748. This phosphorylation site
was initially discovered in 2008 in the context of an examination regarding cell cycle
regulation (Daub et al., 2008). In a previous study of our group, this phosphorylation
was idntified as an autophosphorylation event and an antibody recognizing the
phosphorylated state of this residue was generated (outlined in the dissertation of
Chrisovalantis Papadopoulos, 2011). Bases on this, this phosphorylation was further
investigated in the current work.
3.3.1 Inhibition of serine 748 phosphorylation by harmine and AnnH75
First, the question was investigated if harmine and the new inhibitor AnnH75 are
able to inhibit the autophosphorylation of serine on position 748 or not. Accordingly,
HEK293 cells were used, which were stably transfected with GFP-DYRK1A wild
type (Sitz et al., 2008) and treated with two concentrations of AnnH75 and harmine as
indicated. Immunodetection with the specific antibody pS748 showed slight inhibitory
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Figure 33: Phospho-serine 748 inhibition in HEK cells.
Stable transfected HEK293-TetON-GFP-DYRK1A cells were treated with 10 µM and 1 µM AnnH75
and harmine as indicated for 24 h. Cells were lysed natively and the kinase was purified with GFP-Trap
magnetic beads.
A representative Western blot analysis (A) is shown, as well as densitometric evaluation of phospho-serine
748 inhibition in comparison to phospho-tyrosine inhibition of AnnH75 (B) and harmine (C) of three
independent experiments.
effects after treatment with 1 µM AnnH75 and harmine, respectively. Both inhibitors
were able to inhibit the autophosphorylation activity on serine 748 of DYRK1A at
concentrations of 10 µM entirely, while phospho-tyrosine signals were still detectable
at this concentration (fig. 33). Moreover, both β-carbolines showed a very similar
pattern of inhibitory effects on the autophophorylation activity of tyrosine residues
and serine on position 748.
Next, it was investigated whether the autophosphorylation of serine 748 can be
rephosphoryated as it was demonstrated for tyrosine autophosphorylation events
(cf. fig. 25, cf. fig. 27). Once more stably transfected HEK293-TetON-GFP-DYRK1A
cells were treated with AnnH75 and harmine, but DYRK1A was additionally
incubated with ATP after purification with GFP-Trap magnetic beads. Western blot
analysis showed that DYRK1A was able to rephosphorylate not only tyrosine residues
but also the serine residue on position 748 (fig. 34). This rephosphorylation event
seemed to be weaker regarding phospho-signal intensity at higher concentrations, but
in general even possible at high concentrations independent from the used inhibitor.
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Figure 34: Phospho-serine 748 rephosphorylation.
Stable transfected HEK293-TetON-GFP-DYRK1A cells were treated with AnnH75 and harmine as
indicated for 24 h. After native lysis and kinase purification with GFP-Trap magnetic beads, DYRK1A was
incubated with 100 µM ATP for 1 h at 37°C. A representative Western blot analysis of two independent
experiments is shown.
3.3.2 Inhibition of serine 748 phosphorylation of DYRK1A Y321F
Another subject to this investigation was, whether the autophosphorylation of serine
748 in the DYRK1A point mutant Y321F, as model for the translational folding
intermediate form, can be also inhibited. Transfected HeLa cells were lysed and
purified GFP-fused constructs were incubated with different harmine concentrations
with or without ATP. Wild type DYRK1A was used as control and Western blot
analysis confirmed that both tyrosine and serine autophosphorylation were inhibited
by harmine, although with different potencies (fig. 35). Without ATP incubation, the
uninhibited point mutant of DYRK1A still showed a detectable autophosphorylation
signal for serine on position 748, although this phosphorylation signal was weaker
than after ATP incubation and weaker than in wild type DYRK1A. Treatment
with different harmine concentrations did not modify the signal intensity of serine
748 phosphorylation of GFP-DYRK1A-Y321F, while tyrosine phosphorylation of the
point mutant was inhibited at higher harmine concentrations (fig. 35).
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Figure 35: Phospho-serine 748 inhibition of DYRK1A Y321F.
HeLa cells were transfected with wild type GFP-DYRK1A or GFP-DYRK1A-Y321F, respectively. After
native lysis and kinase purification with GFP-Trap magnetic beads, DYRK1A constructs were incubated
with different harmine concentrations and with or without 500 µM ATP for 1 h at 37°C. A representative
Western blot analysis of two independent experiments is shown.
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4 Discussion
4.1 AnnH75: a potent and selective DYRK1A inhibitor
Harmine is one of the most potent and selective DYRK1A inhibitors, but its
application as chemical probe is restricted by its inhibitory effects on MAO A. Other
known DYRK1A inhibitors show high potencies for DYRK1A inhibition, but lack
selectivity or cell permeability and can be used only in a limited way in biological
systems or animal experiments. This study aimed to find a new DYRK1A inhibitor
that fulfills important criteria for specific investigation of DYRK1A functions in
biological systems, cell assays and animal testing.
The new β-carboline AnnH75 is a chlorine analogue of harmine with an alkylation on
the nitrogen of the pyrrole and was synthesized as part of a series of new β-carboline
compounds. Although AnnH75 is an analogue of harmine, the inhibitory effect on
MAO A was successfully eliminated, while a high selectivity was retained (fig. 14). A
key criterion for the use of a kinase inhibitor as a chemical probe is that its selectivity
profile is well defined (Cohen, 2009, Workman and Collins, 2010). Consequently,
AnnH75 was screened against a panel of 300 wild-type protein kinases. This screening
identified only four off-targets that are inhibited by more than 90% and only further
seven kinases are inhibited by more that 50% at a concentration of 1 µM (fig. 15).
This kinase selectivity profile as well as the Gini coefficient as a parameter for the
overall kinase inhibitor selectivity is comparable to harmine. In contrast, only few
other DYRK1A inhibitors have been profiled against an informative panel of kinases
(Becker et al., 2014).
One known inhibitor of DYRK1A is INDY, which was screened against a panel of
66 protein kinases revealing a lower selectivity at a higher concentration (Gini value
of 0.342 at 10 µM, cf. table 4 and Ogawa et al., 2010). This DYRK1A inhibitor
likewise shows no inhibitory effects on MAO A, but presently nothing is known about
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its pharmakokinetic properties in living animals (Becker et al., 2014). Cell assays
showed that concentrations of 3 µM INDY and higher are needed for inhibition of
tau phosphorylation by DYRK1A (Ogawa et al., 2010). The direct comparison of
DYRK1A inhibition of SF3B1 phosphorylation in cell culture showed that AnnH75 is
more potent than INDY, indicating a better cell permeability of AnnH75 (cf. fig. 19).
Another known DYRK1A inhibitor leucettamine B shows a higher selectivity than
AnnH75 at a higher concentration (Gini value of 0.862 at 10 µM, cf. table 4). The
IC50 value for DYRK1A inhibition was determined to 2.8 µM (Debdab et al., 2011)
and thus is fifteen times higher than for AnnH75 (184 nM, cf. fig. 13). In fact,
leucettamine B should be rather called a CLK1 inhibitor than a DYRK1A inhibitor
with an IC50 value of 0.4 µM for CLK1 (Debdab et al., 2011). Unfortunately, many
inhibitors of DYRK1A show a high potency for CLK1 and some of the other CLK
family members (cf. table 4, Tahtouh et al., 2012, Ogawa et al., 2010, Cuny et al., 2012,
Wippich et al., 2013, Schmitt et al., 2014). This crossreactivity of CLKs and DYRKs
indicates a shared similar geometry of the ATP-binding pocket of these kinases and
reflects their relatively close neighborhood in the CMGC branch of the phylogenetic
kinome tree (cf. fig. 15, Manning et al., 2002).
The leucettamine B analogue leucettine L41 has been synthesized to enhance the
inhibitory effect on DYRK1A and indeed the IC50 value was improved in comparison
to leucettamine B (IC50(L41) = 60 nM, Tahtouh et al., 2012). However, leucettine L41
is less selective than its lead structure (Gini value of 0.673 at 10 µM, cf. table 4), but
it could be shown that leucettine L41 is able to bind DYRK1A in mouse brain tissues
and to inhibit DYRK1A activity in cell culture (Tahtouh et al., 2012). Although a
direct comparison of DYRK1A inhibition of SF3B1 phosphorylation in a cell assay
revealed that leucettine L41 is more potent than AnnH75 (cf. fig. 19), leucettine L41 is
restricted by its lower selectivity. A general comparison between the chosen DYRK1A
inhibitors showed that β-carbolines like harmine, AnnH75 and compound 42 (Cuny
et al., 2012) have much lower inhibitory cross-reactivities against DYRK2, HIPK1-4
and IRAK1 than leucettine L41 (cf. table 4).
4 DISCUSSION 72
The thiophene compounds 29 and 48 were synthesized as dual and selective
DYRK/CLK inhibitors with focus on DYRK1B inhibition (Schmitt et al., 2014).
Nevertheless, the IC50 values for DYRK1A and DYRK1B are very similar for both
compounds (Schmitt et al., 2014). They were screened against a panel of 102 protein
kinases revealing Gini values of 0.741 and 0.724 for compound 29 or 48, respectively
at a concentration of 5 µM, corresponding to a higher selectivity in comparison to
AnnH75. However, there is no specific cell assay for DYRK1A inhibition for these two
thiophene compounds available.
The polyphenolic compound of green tea EGCG is known to inhibit DYRK1A in
a noncompetitive manner (Adayev et al., 2006), but there is also a great number
of putative targets of EGCG known (Tachibana et al., 2004, Chen et al., 2005,
Khan et al., 2006, Yang et al., 2009). In fact, EGCG is the only DYRK1A inhibitor
for which the efficacy was tested in a clinical trial with Down Syndrome patients
(ClinicalTrial identifier: NCT01394796), but its low selectivity is a limiting factor
for testing DYRK1A specific mechanisms in biological systems. A comparison of the
selectivity parameter Gini coefficient is not possible, because for this frequently used
compound there is no profile screening published .
The atypical protein kinase haspin appears to be typically inhibited by β-carbolines
(cf. table 4). But recently published data show that also chemically unrelated
compounds have inhibititory potencies against DYRKs and haspin, e.g. acridines
(Cuny et al., 2010) and the anthrapyrazolon SP600125 (Gao et al., 2013). Although
DYRKs and haspin have only a limited similarity regarding their amino acid sequence,
the conformational features of the ATP-binding pocket appear to be similar and
responsible for this crossreactivity.
In summary, this study showed that the new β-carboline AnnH75 has a cell
permeability comparable to harmine (fig. 17), a low cytotoxicity in HeLa and PC12
cells (table 6) and a good selectivity profile (fig. 15). Therefore, AnnH75 is usable as
a specific inhibitor for investigation of DYRK1A functions in biological systems.
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4.1.1 Structure-inhibition relationship of new β-carboline DYRK1A
inhibitors
The synthesis of the new β-carboline compounds and their screening against
DYRK1A, some related kinases and MAO A was also used to gain further information
about the relationship between structural variances and their effects on the inhibitory
potency.
One special group of β-carboline analogues are the desaza-harmines, which were
synthesized to prove if both nitrogens of the harmine scaffold are essential for the
inhibition of DYRK1A and MAO A as proposed by Reniers et al., 2011 and Becker
and Sippl, 2011 (cf. 2.1.1.1). The replacement of the nitrogen on position 2 by a
carbon in compound AnnHOG3 led to a loss of inhibitory potency against MAO A,
DYRK1A and CLK1 (cf. table 5). Consequently, this pyridine nitrogen is an important
site for the interaction of these three kinases with β-carboline compounds. According
to the model of the DYRK1A/harmine complex (cf. fig. 7, Becker and Sippl, 2011),
AnnHOG3 is no longer able to build a hydrogen bond to the lysine on position 188
(K188) in DYRK1A. A missing hydrogen bond between K188 and an essential water
molecule is responsible for the loss of MAO A inhibition (Reniers et al., 2011) and
the loss of CLK1 inhibition is caused by a missing hydrogen bond with the lysine on
position 191 (fig. S5).
The other nitrogen on position 9 of harmin was replaced with different functional
groups (cf. fig. 16) to make additional sites available for interactions with DYRK1A
or the other kinases. However, non of these 9-desaza analogues of harmine showed an
improved inhibitory potency for DYRK1A in comparison to the lead structure harmine
(cf. table 5). Neither a ketone (AnnHT2), nor an alcohol (AnnHT3), nor a phenol
(AnnHT6) enabled a better interaction with DYRK1A. Only AnnHT5, a 9-desaza
analogue with a cyanomethyl group, showed a DYRK1A inhibition comparable to
harmine, but no inhibitory potency against MAO A (cf. table 5). The other 9-desaza
analogues still showed strong inhibitory effects for MAO A, indicating that the
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nitrogen on position 9 itself is not crucial for the inhibitory potency of a β-carboline
against MAO A, but the size and the orientation of the substituent may be more
important.
Additionally, also the other new β-carboline compounds were analyzed to provide
informations about structural requirements for a selective and potent DYRK1A
inhibitor devoid of MAO-inhibiting activity. Therefore, the newly synthesized
compound structures were compared to each other and analyzed involving co-crystal
structures of harmine bound to DYRK1A (Becker and Sippl, 2011, Ogawa et al., 2010).
This comparison confirmed results of previous co-crystallizations of DYRK1A with
some other inhibitors like INDY (cf. fig. 9, Ogawa et al., 2010 / PDB accession 3ANQ)
or leucettine L41 (Tahtouh et al., 2012). Hence, the pyridine nitrogen on position 2
and the methoxy group substitution on position 7 of harmine play an essential role
for binding with DYRK1A. The importance of the methoxy group substitution on
position 7 can be demonstrated by harmane, which does not posses this substituent
and consequently shows no inhibitory potency for DYRK1A and additionally for
CLK1. In both cases an interaction with this methoxy group seems to be essential
for an inhibition of DYRK1A and CLK1. These outcomes are also compatible with
a binding mode model of AnnH75 and DYRK1A (fig. 36). This model shows that
also AnnH75 forms hydrogen bonds between the nitrogen on position 2 and the lysine
on position 188 in DYRK1A as well as between the methoxy group substitution on
position 7 and the lysine on position 241 in DYRK1A. There are no additional water
molecules involved in this binding as it is known for the binding of harmine with MAO
A (Reniers et al., 2011). Additionally, another hydrogen bond seems to be made by the
pyridine nitrogen on position 2 with the glutamic acid on position 203 in DYRK1A
(fig. 36A). The direct comparison of the binding modes of harmine and AnnH75
shows that both inhibitors make comparable hydrogen bonds, but they reveal different
orientations of some amino acids of the DYRK1A ATP-binding pocket (fig. 36C).
Harmine seems to be slightly rotated in the ATP-binding pocket of DYRK1A, moving
the pyridine nitrogen on position 2 closer to the lysine on position 188 of DYRK1A
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and consequently forming a tighter contact. The different orientation of AnnH75 may
be caused by the additional hydrogen bond, by the weaker basicity of the nitrogen on
position 2 due to the electronegative polarity of the chlorine substituent on position 1
or by the steric constrains of the other substituent of AnnH75.
Figure 36: Model of the DYRK1A/AnnH75 complex.
Binding mode of AnnH75 in DYRK1A showing interacting amino acid residues and hydrogen bonds as
dashed lines. Nitrogen atoms are colored blue, chlorine green and oxygen red.
A, Close-up of DYRK1A ATP-binding pocket with docked AnnH75 in stick representation.
B, Surface representation of the DYRK1A ATP-binding pocket shown in ball representation.
C, Comparison of inhibitor orientations of AnnH75 and harmine in the DYRK1A ATP-binding pocket.
Green side chains of DYRK1A demonstrate the orientation of involved amino acids with bound harmine,
light gray chains with bound AnnH75.
(All structures are generated by Prof. Stefan Knapp (University of Oxford, Target Discovery Institute,
Oxford, Oxfordshire, United Kingdom.))
In AnnH75, the pyrrole nitrogen on position 9 is substituted with a cyanomethyl
group, which could be responsible for a reduced inhibitory potency against MAO
A (cf. AnnHT5), but does not reduce DYRK1A inhibition. In case of AnnH31, this
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cyanomethyl group also led to a potent DYRK1A inhibition, but MAO A was still
inhibited although with a lower potency. It might be possible that the polarity of
the methyl group on position 1 of AnnH31 interacts in some way causing a better
inhibitory potency. However, the cyanomethyl group still provides a potent inhibition
of DYRK1A and CLK1. In case of AnnH75, the binding mode model shows that
binding of this cyanomethyl substituted β-carboline leads to a flip of the phenylalanine
on position 238 of the P-loop of DYRK1A into the ATP-binding pocket, although the
cyanomethyl group seems to impede the P-loop of DYRK1A without interacting with
any amino acid (fig. 36). However, this conformational change can be also observed
in DYRK1A/inhibitor complexes with harmine (cf. fig. 7, Becker and Sippl, 2011),
INDY (cf. fig. 9, Ogawa et al., 2010) and leucettine L41 (Tahtouh et al., 2012) and
seems to be typical for the ATP-binding pocket or the P-loop of DYRK1A.
Additionally, the structure comparison of the newly synthesized compounds revealed
that all modifications on positions 6 and/or 8 of the harmine scaffold led to the loss of
the inhibitory potency for DYRK1A. Especially halogenic substituents like chlorine
and bromine were tested, because it is known that a chlorine participates in the binding
of KH-CB19 and CLK (Fedorov et al., 2011). But all these halogenic substitutions
showed the same effect on DYRK1A inhibition. However, these substituents do not
determine the inhibitory potency for MAO A, because there is no common pattern
evident. Actually, an increased affinity of harmine for DYRK1A after addition of small
substituents on the indole ring had been presumed, but this does not seem to hold
true for halogenic substituents.
Another objective of this study was to decrease the CLK1 inhibitory potency of
DYRK1A inhibitors. However, all potent new synthesized DYRK1A inhibitors showed
also potent inhibitory activity for CLK1. This is due to the similar geometry of
the ATP-binding pocket in these two kinases and it reflects their relatively close
neighborhood in the CMGC branch of the phylogenetic kinome tree (cf. fig. 15,
Manning et al., 2002). Only the amino methyl carbonyl compound AnnH28_2 showed
a low inhibitory potency for CLK1 and the other tested related kinases of DYRK1A
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(cf. table 2). The inhibition of DYRK1A itself was also not as potent as in case of
other newly synthesized β-carboline compounds and therefore this compound was not
further investigated.
Interestingly, there was no newly synthesized carboline compound with a high potency
for DYRK2. The strongest inhibition was measured after treatment with AnnH75
leading to a residual activity of DYRK2 of 42% (cf. table 2). In general, β-carbolines
seemed not to be able to inhibit DYRK2 potently. It is possible that the binding
mode of β-carbolines in class II DYRKs is influenced by the NAPA region or
by a changed geometry of the ATP-binding pocket due to non-conserved residues.
According to Soundararajan and co-workers (2013) the NAPA region of DYRK2
folds a small domain that stabilizes the N-terminal lobe of the kinase domain, which
may influence the binding mode of class II DYRKs. Existing co-crystal structures
of DYRK2 with leucettine L41 shows that the hydrogen-bonding interactions in this
complex are mediated by water molecules (Tahtouh et al., 2012). Furthermore, it
could be shown that the change of a methionine in DYRK1A to a leucine in DYRK2
opens the ATP-binding pocket and slightly decreases hydrophobicity. Additionally,
this co-crystal structure shows that the isoleucine preceding the DFG motif in DYRK2
changes the hydrophobic contact surface for leucettine L41 significantly (Tahtouh et
al., 2012). It still remains to be clarified if all these changes are pivotal for the low
inhibitory potency of β-carbolines against DYRK2.
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4.2 Dual specificity kinase activity of DYRK1A
Dual specificity kinase activity is an outstanding feature of the DYRK
family and is essentially linked to the characteristic mechanism of tyrosine
autophosphorylation activity of DYRKs. The current model of the mechanism of
tyrosine autophosphorylation in the DYRK family is based on a study of the
Drosophila DYRKs dDYRK2 and MNB (Lochhead et al., 2005), but has not been
verified for mammalian DYRK1A yet. This model postulates the activation of DYRKs
by a co-translational, one-time tyrosine autophosphorylation in the activation loop.
This part of the study investigates whether tyrosine phosphorylation is a strictly
co-translational event or whether it can still take place in mature DYRKs. Further, it
deals with the potential of inhibitors to differentially target the tyrosine kinase form
and/or the mature serine/threonine-specific conformation of DYRK1A.
4.2.1 Posttranslational tyrosine kinase activity of DYRK1A is not limited
to the conserved tyrosine 321 in the activation loop
In vitro translation of DYRK1A revealed that tyrosine phosphorylation signals
temporally appear up to 1 h before the production of the protein is detectable
(cf. fig. 24). This finding is consistent with the model of a co-translational
autophosphorylation mechanism, where the presence of small N-terminal domains,
which are capable of folding independently, stabilizes and enables a catalytically
active conformation during translation (Soundararajan et al., 2013). The assumed
mechanism had already been shown for Drosophila dDYRK2 (Lochhead et al., 2005)
and a very similar kinetic was recently reported for HIPK2 (Saul et al., 2012).
In both cases, tyrosine phosphorylation paralleled the protein production of these
kinases. In contrast, the tyrosine autophosphorylation of the related kinase GSK3β
depends on the chaperone activity of heat shock protein 90 kDa and the tyrosine
autophosphorylation signal delays the detection of the protein (Lochhead et al., 2006).
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Additionally, this study shows that DYRK1A retains the capacity of
autophosphorylating tyrosine residues after termination of in vitro translation.
This ability has been thought to be strictly limited to cis-autophosphorylation of
one specific tyrosine residue in the activation loop in DYRKs (Lochhead et al.,
2005), GSK3β (Lochhead et al., 2006) and HIPK2 (Saul et al., 2013). After in vitro
translation in presence of the unspecific inhibitors 5-Iodotubercidin or staurosporine,
the unphosphorylated DYRK1A still had the ability to autophosphorylate on tyrosine
residues (cf. fig. 25). The same ability was observed for the Y321F point mutant
of DYRK1A (cf. fig. 26). These results were confirmed by another experimental
setup, where the inhibitor was diluted after translation to a concentration without
inhibitory effects on DYRK1A (cf. fig. 27). In Conclusion, inhibitor treatment
might have arrested the catalytic domain in the nascent conformation, allowing
delayed autophosphorylation after washout of the inhibitor. Accordingly, tyrosine
kinase activity of DYRK1A is not limited to a transient folding state that only
exists during translation. Furthermore, it can be assumed that the ability of
DYRK1A for posttranslational tyrosine autophosphorylation does not depend
on the phosphorylation status of the conserved tyrosine 321 in the activation
loop. Consistently, the capability of DYRK1A to autophosphorylate tyrosine
residues in mature, folded proteins in vitro is confirmed by a DYRK1A protein
monophosphorylated on tyrosine 321, which was still able to autophosphorylate
several other tyrosine residues (Soundararajan et al., 2013). Additionally, the same
phenomenon was shown for the Y321F point mutant of DYRK1A, which was
not phosphorylated after expression, but also shows autophosphorylation activity
(Soundararajan et al., 2013). It must be noted that determining the distances
between the active site and the phosphorylated tyrosine residues suggest that most
of these additional phosphorylated tyrosine residues were carried out in trans rather
than in cis (Soundararajan et al., 2013). Also the DYRK orthologue from yeast,
Yak1p, has been shown to autophosphorylate on tyrosine when immunoprecipitates
were incubated with ATP (Kassis et al., 2000). In addition, HIPK2 has been shown
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to be capable of rephosphorylating the conserved activation loop tyrosine residue in
the presence of ATP after in vitro dephosphorylation of the mature enzyme (Siepi et
al., 2013). Furthermore, the same study showed that also the HIPK2 point mutant
with substituted activation loop tyrosine was capable of residual autophosphorylation
activity, although the autophosphorylation of this activation loop tyrosine is a critical
site to acquire kinase activation, substrate specificity, and subcellular localization of
HIPK2 (Siepi et al., 2013). Consistently, these outcomes and the fact that in E. coli
or in vitro expressed DYRK1A Y321F point mutants were phosphorylated besides
the conserved activation loop tyrosine (cf. fig. 23) reveals that this activity is not
strictly limited to one special tyrosine.
However, it is important to note that none of these results contradict the hypothesis
that the autophosphorylation in the activation loop is a one-time-only event, as it was
postulated by Lochhead and co-workers (2005) for Drosophila dDYRK2. Although
the structures of DYRK1A and DYRK2 both show a completely ordered activation
segment in a similar conformation with the tyrosine residue in the activation loop as
main mediator of stabilizing interactions (Soundararajan et al., 2013), the activation
loop tyrosine cis-autophosphorylation of DYRK2 seems to be more important for its
kinase activity (cf. fig. 23A), while DYRK1A kinase activity seems not to depend
on this autophosphorylation event. Nevertheless, it may be also possible that this
construct of DYRK2 is not able to phosphorylate other tyrosine residues although
it is still active. Additionally, recently published data reveal that the Y382F point
mutant of DYRK2 shows detectable posttranslational tyrosine kinase activity when
immunoprecipitates from HeLa cells were incubated with ATP (Walte et al., 2013).
Furthermore, this capacity of autophosphorylating tyrosine residues after termination
of translation of DYRK2 Y382F point mutants is still sensitive to inhibition by
5-Iodotubercidin (Walte et al., 2013). This is indicating that also in DYRK2 the
inhibition of the conserved activation loop tyrosine phosphorylation does not remove
the catalytic activity of the kinase per se, as it has already been shown for HIPK2
(Siepi et al., 2013) and DYRK1A.
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4.2.2 Differential inhibitor sensitivities of mature DYRK1A and the
translational intermediate
According to Lochhead and co-workers (2005) it should be possible to find a specific
and irreversible inhibitor, which differentially targets the translational intermediate
form with tyrosine kinase activity and the mature serine/ threonine-specific
conformation of DYRK1A. Consistently, the wild type DYRK1A corresponds to the
mature form able to phosphorylate only on serine and /or threonine residues, while
the Y321F point mutant corresponds to the translational folding intermediate form
which is able to autophosphorylate tyrosine residues.
Harmine as well known DYRK1A inhibitor does not show discriminable differences
of inhibiting those two conformational forms of DYRK1A (cf. fig. 28). Also other
different chemical scaffolds were tested for their inhibitory potency towards inhibiting
the autophosphorylation of tyrosine residues and substrate phosphorylation of wild
type DYRK1A and the Y321F point mutant, respectively. As expected, the potency of
the tested inhibitors for inhibiting the autophosphorylation did not differ between both
tested DYRK1A forms (cf. fig. 29, upper panels). During the in vitro translation also
wild type DYRK1A is in the condition of the translational folding intermediate form
and consequently an inhibitor has to inhibit in the same way as it inhibits the Y321F
point mutant. Specifically the subsequent substrate phosphorylation can be inhibited
differently, but only TBB showed a differential inhibition of wild type DYRK1A and
the Y321F point mutant at a concentration of 30 µM, but not at higher concentrations
(cf. fig. 29, lower panel). While the translational intermediate form of DYRK1A
was inhibited in substrate phosphorylation activity, the mature DYRK1A was not
inhibited. TBB has already been used to establish the differential inhibitor sensitivity
of dDYRK2, which is specifically inhibited by this inhibitor in the conformation of the
mature form with serine/ threonine-specific activity (Lochhead et al., 2005). Providing
that tyrosine autophosphorylation is essential for maturation of DYRKs and given that
this mechanism is conserved throughout the DYRK family, the Y321F point mutant of
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DYRK1A should be unable to achieve the mature conformation and thus be resistant
to compounds that selectively target the mature conformation of DYRKs, in this case
TBB. Consequently, also the dose response curves for substrate phosphorylation of
wild type DYRK1A and the Y321F point mutant should differ, but they did not
(cf. fig. 30). Consistently, the differential inhibition of TBB remains an unexplained
peculiarity of the in vitro expression system and the kinase inhibitor sensitivities of
tyrosine autophosphorylation of mature DYRK1A and the translational intermediate
form of DYRK1A do not differ either.
Additionally, all tested compounds inhibited the substrate phosphorylation of SF3B1
much more potently than tyrosine autophosphorylation of DYRK1A (cf. fig. 29). This
also has been previously reported for harmine (Göckler et al., 2009). This difference
was not caused by the differential inhibition of both conformations of DYRK1A, but
shows that the DYRK1A autophosphorylation assay is less sensitive to the known
DYRK inhibitors than the substrate phosphorylation assay. Repetition of this assay
with a DYRK1A construct fused to a SF3B1 sequence for enabling a co-translational
phosphorylation of both autophosphorylation and substrate phosphorylation under
same conditions revealed that the preferential inhibition of threonine phosphorylation
was lost (cf. fig. 31). However, it must be noted that it is impossible per se to
perform autophosphorylation assays under conditions of substrate saturation. At least
minimal catalytic activity is needed to allow this one catalytic cycle to proceed that
is required for stoichiometric autophosphorylation within 2 h of incubation time.
Therefore, even strong inhibition of catalytic activity hardly reduces the amount of
autophosphorylated kinase (Walte et al., 2013).
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4.2.3 Tyrosine autophosphorylation of other CMGC kinase family
members
Since 1998 it is known that an expression construct of the yeast kinase Yak1p
consisting only of the catalytic domain and the adjacent DYRK homology box
is able to autophosphorylate on tyrosine residues when expressed in E. coli
(Becker et al., 1998). In this study also analogous constructs of the other DYRK
family members as well as the related kinases HIPK2, CDKL5, PRP4 and CLK1 were
analyzed regarding their capability of tyrosine autophosphorylation. After expression
in E. coli, constructs of DYRK1A, DYRK2, HIPK2 and CLK1 showed tyrosine
autophosphorylation activity (cf. fig. 22). Unexpectedly, the NAPA region was not
required for this activity in DYRK2, although the sequence motif is well conserved in
the human protein. It is possible that the function of the NAPA region differs between
individual kinases of different organisms, like human DYRK2 versus Drosophila
dDYRK2 and Trypanosoma brucei TbDYRK2 (Kinstrie et al., 2010, Han et al.,
2012) or that the differences are justified in the contrasting experimental systems used
(expression in E. coli versus rabbit reticulocyte lysate). It must be also noted that
this result does not provide direct evidence for a NAPA-independent phosphorylation
of the activation loop, because the antibody does not discriminate between the
phosphorylation of the tyrosine residue in the activation loop and other tyrosines.
Kinases of the CLK family lack a conserved tyrosine in the activation loop, although
these kinases are able to autophosphorylate on tyrosine residues in vitro or in bacterial
expression systems (Lee et al., 1996, Savaldi-Goldstein et al., 2000). For the family
member CLK3 a tyrosine phosphorylation activity could be shown when expressed
in HeLa cells. However, this tyrosine phosphorylation was strongly stimulated
after treatment with sodium vanadate, revealing for the first time that CLKs can
autophosphorylate on tyrosine in a homologous expression system (Walte et al., 2013).
For the family member CLK1 it has been reported that its catalytic activity is
unaffected by exposure to tyrosine phosphatases (Menegay et al., 2000). Specification
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of a potential regulatory function of tyrosine autophosphorylation in CLKs remains to
be determined, although a positive regulation by phosphorylation on tyrosine residues
is speculated (Menegay et al., 2000). However, it must be noticed that dual specificity
kinase activity is a conserved feature even in those CMGC kinases that are not
activated by tyrosine phosphorylation, indicating that the specific feature of dual
specificity kinase activity is a characteristic of CMGC kinases.
4.2.4 Phosphorylation activity on serine 748
It is known that besides from the autophosphorylation of tyrosine residues, DYRK1A
is also able to autophosphorylate on the serine residue on position 748 (Daub et
al., 2008, dissertation of Chrisovalantis Papadopoulos, 2011). This phosphorylation
activity, as well as the autophosphorylation of tyrosine residues, is inhibitable
with harmine and the new β-carboline AnnH75 (cf. fig. 33), confirming that
phosphorylation of serine on position 748 is an autophosphorylation event. After
the additional incubation with ATP, both wild type DYRK1A (cf. fig. 34) and
the point mutant Y321F (cf. fig. 35) are still capable to autophosphorylate on
serine 748. This results confirm the findings for tyrosine autophosphorylation that
the ability of DYRK1A for posttranslational autophosphorylation does not depend
on the phosphorylation status of the conserved tyrosine 321 in the activation
loop. This specific serine residue is located in the consensus sequence of substrate
phosphorylation of DYRK1A (Himpel et al., 2000), merely the proline on position -2
relative to the phosphorylation residue is not present. Previous studies of our group
have revealed that the phosphorylation of serine on position 748 occurs as an
intermolecular reaction essentially dependent of the kinase activity on DYRK1A
(dissertation of Chrisovalantis Papadopoulos, 2011).
Another serine autophosphorylation site was already reported in 2007 and identified
as serine on position 520, located in the PEST domain of the protein. This
autophosphorylation event was shown to be an intramolecular mechanism without
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effect on the intrinsic kinase activity itself (Alvarez et al., 2007). Additionally, it could
be shown that this phosphorylation site is required for binding to the regulatory
protein 14-3-3β and consequently for contributing to a regulatory mechanism or
modulation of activity (Alvarez et al., 2007). It remains to be determined whether the
autophosphorylation of serine on position 748 likewise might modulate the activity of
DYRK1A.
4.3 Conclusion
The present study introduces the new harmine analogue AnnH75 as potent and
selective DYRK1A inhibitor with the novel feature that it lacks inhibitory effects
on MAO A. This new β-carboline shows a cell permeability comparable to harmine
and a low cytotoxicity in HeLa and PC12 cells. In conclusion, AnnH75 is a specific
compound suitable for investigations of DYRK1A functions in biological systems.
Furthermore, the synthesis of new β-carboline compounds was used to gain further
information about their structure activity relationship (SAR). SAR revealed that size
and orientation of the substituent on the nitrogen on position 9 of the β-carboline
scaffold is important for the inhibitory potency against MAO A. In contrast, the
binding with DYRK1A is mediated by the pyridine nitrogen on position 2 and the
methoxy-group substitution on position 7 of harmine. Additionally, all modifications
on positions 6 and/or 8 of the harmine scaffold lead to the loss of the inhibitory potency
against DYRK1A. Unfortunately, no inhibitor could be identified with decreased
CLK1 inhibition. Of note, none of the newly synthesized carboline compounds had a
high potency for DYRK2, from which it can be concluded that β-carbolines seem not
to be able to inhibit this DYRK family member potently in general. Differences of
the amino acid sequences, responsible for the low inhibitory potency of β-carbolines
against DYRK2 still remain to be elucidated.
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The second part of this study shows that the tyrosine kinase activity of DYRK1A is
not limited to a transient folding state as it was published for Drosophila dDYRK2
(Lochhead et al., 2005). Furthermore, the ability of DYRK1A for posttranslational
tyrosine autophosphorylation seems not to depend on the phosphorylation status of
the conserved tyrosine 321 in the activation loop of DYRK1A. Finally, none of the
tested specific and irreversible inhibitors for DYRKs combined differential inhibitor
sensitivities for serine/ threonine kinase activity and tyrosine activity of DYRK1A,
although it has been described for Drosophila that a compound with these properties
should exist. In the present study, inhibitors from 7 different chemical classes were
tested in mammalian cells and no discriminable differences regarding the inhibition
of both conformational forms of DYRK1A could be shown. It is very likely that this
discrepancy can be explained by developmental differences between Drosophila and
mammals.
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6 Supplement
6.1 Synthesized harmine analogues
Table S1: Synthesized β-carboline compounds.
All new compounds were synthesized after corporate arrangement with the center for drug research
in the department of pharmacy by collaborators of Prof. Dr. Franz Bracher in Munich (chemistry is
summarized in the dissertation of Anne Wurzlbauer, 2013).
name of compound name of compound name of compound name of compound
AnnH1 AnnH21 AnnH52 AnnH81
AnnH3 AnnH22 AnnH53 AnnH83
AnnH4_4 AnnH24 AnnH55 AnnH88
AnnH5_1 AnnH25 AnnH57 AnnH90
AnnH5_2 AnnH26_5 AnnH59 AnnHOG3
AnnH5_3 AnnH27 AnnH62 AnnHT2
AnnH5_4 AnnH28_2 AnnH63 AnnHT3
AnnH6_1 AnnH30_2 AnnH66 AnnHT5
AnnH6_3_1 AnnH31 AnnH67 AnnHT6
AnnH6_3_2 AnnH32_2 AnnH69 AnnEP2_5
AnnH7_1 AnnH34 AnnH70 bauerin A
AnnH9 AnnH35 AnnH71 DHI-8
AnnH11 AnnH36 AnnH73 DHI-13
AnnH12 AnnH38 AnnH74 DHI-19
AnnH14 AnnH39 AnnH75 harman
AnnH16_4 AnnH40 AnnH76 harmol
AnnH18_5 AnnH42 AnnH77 harmalacidin
AnnH19_4 AnnH43 AnnH79 Kast180-HCl
AnnH20 AnnH44 AnnH80
6.2 Profiling of AnnH75
Table S2: Profiling of AnnH75.
Profiling of AnnH75 at 1 µM against 300 wild-type protein kinases. Residual activities of the
perspective protein kinase of a duplicate measurement made by ProQuinase GmbH (Freiburg,
Germany) are shown. Mean residual activities of 50% and lower are highlighted in grey.
Classification of protein kinase families (Manning et al. Science 6 December 2002: Vol.
298 no. 5600 pp. 1912-1934): AGC: containing PKA, PKG and PKC families, CAMK:
Calcium/Calmoduline-dependent protein kinases, CK1: Casein kinase 1-like, CMGC: containing
CDK, MAPK ,GSK3 and CLK families, TK: Tyrosine Kinase, TKL: Tyrosine Kinase-like, STE:
Homologs of Yeast Sterile 7, Sterile 11, Sterile 20 Kinases, ** Constitutively active kinase.
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6.3 Sequence allignment of CLK1 activation loop
Table S3: Sequence allignment of CLK1 activation loop.
Expression clone for ST2-hCLK1cat encoded the catalytic domain with the indicated amino acids.
A stop codon was introduced immedately after the last amino acid and the human CLK1 cDNA
was amplified by RT-PCR from SH-SY5Y mRNA. NCBI Refseq accession number is available
at http://www.ncbi.nlm.nih.gov/protein. For more information see supplemental material of
Walte et al., 2013.
Fusion protein NCBI Refseq amino acids Allignment of activation loop
ST2-... accesion number (subdomain VII - VIII )
hCLK1cat NP_004062 141-484 DFG SATYDDEHHSTLVSTRHY RAPE
6.4 Structures of used DYRK1A inhibitors
Figure S4: Chemical structures of used inhibitors.
Inhibitors were used for differentiation of tyrosine autophosphorylation and substrate
phosphorylation inhibition (fig. 29).
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6.5 Model of the CLK1/harmine complex
Figure S5: Model of the CLK1/harmine complex.
Close-up of CLK1 ATP-binding pocket with docked harmine. Interacting amino acid residues
are displayed and formed hydrogen bongs are shown as green lines (CLK1/harmine complex was
modeled by W. Sippl for the dissertation of Anne Wurzlbauer, 2013).
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